A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% Adapalene/2.5% BPO), in the Treatment of Acne Vulgaris
Phase: PHASE2
Conditions: Acne Vulgaris
Sponsor: Bausch Health Americas, Inc.

CLINICAL STUDY PROTOCOL 
 
IDP-126 
 
Protocol V01-126A-202 
 
A Phase 2, Multicenter, Randomized, Double-Blind, 
Vehicle-Controlled, Clinical Study to Compare the Safety and 
Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% 
BPO), in the Treatment of Acne Vulgaris 
 
 
Development Phase:  
2 
 
Study Design: 
Multicenter, randomized, double-blind, vehicle-controlled efficacy 
and safety study 
 
Date: 
Version 2.0, 2 March 2021 (Amendment 1) 
Version 1.0, 30 October 2020 (Original) 
 
Sponsor:  
Bausch Health Americas, Inc. 
 
 
 
 
 
 
 
1330 Redwood Way 
 
 
 
 
 
 
 
Petaluma, CA 94954 
 
 
 
 
 
 
 
 
 
For EU:  
 
 
 
EudraCT No.: 2021-000100-37 
 
 
CONFIDENTIAL 
Nothing herein is to be disclosed without prior approval of the sponsor. 
 
 
 
 
 
 
 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
3 
 
Personnel Responsible for Conducting the Study 
 
A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Clinical 
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% 
adapalene/2.5% BPO), in the Treatment of Acne Vulgaris 
 
Contract Research Organization / Medical Monitor 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
4 
 
Principal Investigator Protocol Agreement Page 
I agree: 
• To assume responsibility for the proper conduct of this clinical study at this study 
center and to conduct the study in compliance with this protocol, any future 
amendments, and with any other study conduct procedures provided by the sponsor. 
• That I am aware of, and will comply with, the internationally recognized code of Good 
Clinical Practices (GCP) and all other applicable regulatory requirements to obtain 
written and dated approval from the Institutional Review Board (IRB) or Independent 
Ethics Committee (IEC) for the study protocol, written informed consent, consent form 
updates, subject-recruitment procedures (eg, advertisements), and any other written 
information to be provided to the subjects, before initiating this clinical study. 
• Not to implement any changes to, or deviations from the protocol without prior 
agreement from the sponsor and review and documented approval from the IRB/IEC, 
except to eliminate an immediate hazard to the study subjects, or when change(s) 
involves only logistical or administrative aspects of the clinical study. 
• To permit direct monitoring and auditing by the sponsor or sponsor’s representatives 
and inspection by the appropriate regulatory authority(ies). 
• That I am thoroughly familiar with the appropriate use of the study drugs(s), as 
described in this protocol, and any other information provided by the sponsor or 
designee, including, but not limited to, the current Investigator Brochure or equivalent 
document and approved product label (if applicable). 
• To provide sufficient time, and adequate numbers of qualified staff and facilities for the 
foreseen duration of the clinical study to conduct the study properly, ethically, and 
safely. 
• To ensure that all persons assisting in this study are adequately informed about the 
protocol, study drug(s), and their clinical study-related duties and functions. 
 
 
 
 
Principal Investigator (print name) 
 
 
 
 
Principal Investigator (signature) 
 
Date 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
5 
 
2 Synopsis 
Name of Sponsor/Company: Bausch Health Americas, Inc. 
Name of Investigational Product: IDP-126 Gel 
Name of Active Ingredients: Fixed combination of clindamycin phosphate 1.2%, benzoyl peroxide 
(BPO) 3.1%, and adapalene 0.15% 
Title of Study: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to 
Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in 
the Treatment of Acne Vulgaris 
Number of Clinical Centers: Multicenter, approximately 40 study centers in North America and Europe 
Objective:  
The primary objective of this study is to establish a clinical bridge for IDP-126 Gel (clindamycin 
phosphate 1.2%, benzoyl peroxide [BPO] 3.1%, and adapalene 0.15%) to the comparator drug Epiduo® 
Forte Gel (0.3% adapalene and 2.5% BPO) in subjects with moderate to severe acne vulgaris. The safety 
and efficacy of once daily application of IDP-126 Gel will be compared to Epiduo® Forte and IDP-126 
Vehicle Gel. 
Methodology:  
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the 
safety, tolerability, and efficacy of IDP-126 Gel in comparison with Epiduo® Forte gel and IDP-126 
Vehicle Gel at Weeks 2, 4, 8, and 12. To be eligible for the study, subjects must be at least 12 years of age 
and have a clinical diagnosis of moderate to severe acne (defined as an Evaluator’s Global Severity Score 
[EGSS] of 3 or 4), presenting with 30-100 inflammatory facial lesions (papules, pustules, and nodules), 
35-150 non-inflammatory facial lesions (open and closed comedones), and ≤ 2 facial nodules.      
All subjects will receive once daily, topically applied treatment to the face for 12 weeks. Subject visits 
include Screening, Baseline, Week 2, Week 4, Week 8, and Week 12, at which safety and efficacy 
assessments will be conducted (Screening and Baseline may occur on the same day if no washout is 
required). One pump of study drug will be dispensed to the subjects at the Baseline, Week 4, and Week 8 
study visits. Subjects will be evaluated for drug usage compliance at each post baseline study visit (Weeks 
2, 4, 8, and 12). Subjects will apply their treatments at home, once daily (in the evening), as instructed by 
the study coordinator or designee at each study center.  
The investigator will assess the subject’s face at each study visit. Though not a requirement for study 
inclusion, the subject may be assessed for truncal acne (neck, upper chest, upper back and shoulders). If 
the subject has truncal acne and would like to apply study drug to these area(s) a separate evaluation will 
be performed to assess truncal acne using a Truncal Severity Score (TSS). TSS will be conducted at 
Baseline, Week 2, Week 4, Week 8, and Week 12. Subject participation in treatment of truncal acne is not 
a requirement. 
Information on reported and observed AEs will be obtained at each visit. An abbreviated physical 
examination and vital sign measurements will be performed at Baseline and Week 12 (end of study) for all 
subjects. Blood samples will be collected from subjects at Baseline and Week 12, for CBC/Diff and serum 
chemistry. For all female subjects of childbearing potential (FOCBP), urine pregnancy testing will be 
performed at Screening, Baseline (prior to randomization), and at Weeks 2, 4, 8, and 12. Additionally, 
serum pregnancy testing will be performed at Baseline and Week 12. 
In addition, at selected study centers, standardized photography of the face will be performed at Baseline, 
and Weeks 4, 8 and 12. 
Number of subjects planned:  
Approximately 660 subjects will be randomized in a 2:2:1:1 ratio to the following treatment groups: 
• 
220 Subjects to IDP-126 Gel (clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%) 
• 
220 Subjects to Epiduo® Forte Gel (adapalene 0.3%/BPO 2.5%) 
• 
110 Subjects to IDP-126 Vehicle Gel (stored at 2-8°C) 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
6 
 
• 
110 Subjects to IDP-126 Vehicle Gel (stored at controlled room temperature (CRT)) 
Inclusion criteria:  
1. Male or female at least 12 years of age and older. 
2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an 
assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches 
age of consent during the study they should be re-consented at the next study visit). 
3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit. 
4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 
30, but no more than 100. 
5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 
35, but no more than 150. 
6. Subjects with 2 or fewer facial nodules. 
7. FOCBP and females who are premenses must be willing to practice effective contraception for the 
duration of the study. (Effective contraception is defined as stabilized on oral [either combined 
estrogen and progestogen containing of progestogen only] contraceptive for at least 3 months, 
intrauterine device/system, condom with spermicide, diaphragm with spermicide, implant, 
NuvaRing®, injection, transdermal patch, bilateral occlusion, vasectomized partner, or abstinence.) 
Females on birth control pills must have taken the same type pill for at least 3 months prior to 
entering the study and must not change type during the study. Those who have used birth control pills 
in the past must have discontinued usage at least 3 months prior to the start of the study. Women who 
use birth control for acne control only should be excluded. 
8. Premenses females and FOCBP must have a negative urine pregnancy test at Screening Visit, and a 
negative urine pregnancy test at Baseline Visit. 
9. Subjects must be willing to comply with study instructions and return to the clinic for required visits. 
Subjects under the age of consent must be accompanied by the parent or legal guardian at the time of 
assent/consent signing; 
10. If a cleanser, moisturizer or sunscreen is needed during the study, subjects must be willing to use only 
allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products (see 
Appendix 17.2). Subjects must agree to use non-comedogenic products (including makeup and 
shaving products). 
Exclusion Criteria: 
1. Use of an investigational drug or device within 30 days of enrollment or participation in a research 
study concurrent with this study. 
2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne 
conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, 
gram-negative folliculitis, dermatitis, eczema. 
3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of 
interfering topical or systemic therapy or makes evaluations and lesion count inconclusive. 
4. Subjects with a facial beard or mustache that could interfere with the study assessments. 
5. Subjects with more than 2 facial nodules. 
6. Evidence or history of cosmetic-related acne. 
7. Subject has a history of experiencing significant burning or stinging when applying any facial 
treatment (eg, makeup, soap, masks, washes, sunscreens, etc) to their face. 
8. Female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the 
study, or become pregnant during the study. 
9. Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 12 weeks 
immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks 
immediately prior to study entry need not be excluded unless the subject expects to change dose, drug 
or discontinue estrogen use during the study. 
10. If female, subject has a history of hirsutism, polycystic ovarian disease or clinically significant 
menstrual irregularities. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
7 
 
11. History of regional enteritis, ulcerative colitis, inflammatory bowel disease, pseudomembranous 
colitis, chronic or recurrent diarrhea, or antibiotic-associated colitis.  
12. Treatment of any type of cancer within the last 6 months, with the exception of complete surgical 
excision of skin cancer outside the treatment area.  
13. Subject uses medications and/or vitamins during the study which are reported to exacerbate acne 
(azathioprine, haloperidol, Vitamin D, Vitamin B12, halogens such as iodides or bromides, lithium, 
systemic or topical mid-to super-high potency corticosteroids on the treatment area, phenytoin and 
phenobarbital). Multivitamins, including Vitamin A, at recommended daily doses and Vitamin D at 
stable doses, are acceptable. 
14. History of hypersensitivity or allergic reactions to any of the study preparations as described in the 
Investigator’s Brochure, including known sensitivities to any dosage form of clindamycin phosphate, 
BPO, or adapalene. 
15. Concomitant use of potentially irritating over-the-counter products that contain ingredients such as 
BPO, alpha-hydroxy acid, salicylic acid, retinol or glycolic acids. 
16. Subjects who have not undergone the specified washout period(s) for the following topical 
preparations/physical treatments used on the face or subjects who require the concurrent use of any of 
the following in the treatment area: 
Topical astringents and abrasives on the face                                      1 week 
Non-allowed moisturizers or sunscreens on the face 
1 week 
Antibiotics on the face                                                                          2 weeks 
Other topical anti-acne drugs on the face 
2 weeks 
Soaps containing antimicrobials on the face                                        2 weeks 
Anti-inflammatory agents and corticosteroids on the face 
4 weeks 
Retinoids, including retinol on the face 
4 weeks 
Chemical peel/microdermabrasion on the face                                    4 weeks 
Light (eg. LED, PDT) therapy on the face                                           4 weeks 
Acne surgery                                                                                        4 weeks 
Laser therapy on the face                                                                     4 weeks                                      
 
 
17. Subjects who have not undergone the specified washout period(s) for the following systemic 
medications or subjects who require the concurrent use of any of the following systemic medications: 
Corticosteroids (including intramuscular injections)  
    (inhaled corticosteroids allowed)  
4 weeks 
Antibiotics 
4 weeks 
Other systemic acne treatments 
4 weeks 
Systemic retinoids 
6 months 
18. Subjects who intend to use a tanning booth or sunbathe during the study. 
19. Subjects who are unable to communicate or cooperate with the investigator due to language problems, 
poor mental development, or impaired cerebral function. 
20. Subjects with any underlying disease that the investigator deems uncontrolled, and who pose a 
concern for the subject’s safety while participating in the study. 
Investigational product, dosage and mode of administration:  
Investigational Product: IDP-126 Gel (clindamycin phosphate 1.2%, BPO 3.1%, and adapalene 0.15%), 
applied topically to the face once daily for 12 weeks.  
Duration of treatment:  
12 weeks for all subjects. 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
8 
 
Reference therapy, dosage and mode of administration:  
• Epiduo® Forte Gel (adapalene 0.3%/ 2.5% BPO) applied once daily for 12 weeks. 
• IDP-126 Vehicle Gel (stored at 2-8°C) applied once daily for 12 weeks. 
• IDP-126 Vehicle Gel (stored at controlled room temperature) applied once daily for 12 weeks. 
Criteria for evaluation: 
Co-Primary efficacy: 
IDP-126 Gel will be compared to Epiduo® Forte Gel and IDP-126 Vehicle Gel. 
Co-primary endpoints are:  
(1) Absolute change from Baseline to Week 12 in inflammatory lesion counts. 
(2) Absolute change from Baseline to Week 12 in non-inflammatory lesion counts. 
(3) Percentage of subjects who achieve at least a two-grade reduction from baseline and are “Clear” or 
“Almost Clear” at Week 12 in the Evaluator’s Global Severity Score. 
Secondary efficacy: 
The secondary endpoints to be summarized using descriptive statistics are: 
(1) Absolute change in inflammatory and non-inflammatory lesion counts from baseline at 
Weeks 2, 4 and 8 
(2) Percent of subjects who achieve at least a 2-grade reduction from baseline and are 
“clear” or “almost clear” at Week 2, 4 and 8 on EGSS 
(3) Mean percent change in inflammatory and non-inflammatory lesion counts from 
baseline at Weeks 2, 4, 8 and 12.  
Efficacy Measurements: 
Lesion Counts 
At each visit, the evaluator will count the total number of inflammatory lesions (papules, pustules, and 
nodules) on the subject’s face. Nodules will be counted separately but will be included in the total 
inflammatory lesion count. At baseline, eligible subjects may have no more than 2 nodules. Nodules will 
be included in the statistical analysis of inflammatory lesion counts. All inflammatory lesions will be 
counted at the same time rather than counting papules and pustules separately. The evaluator will also 
count the total number of non-inflammatory lesions (open and closed comedones). The same blinded 
evaluator should perform the lesion counts and EGSS evaluations at all visits from baseline to week 12 for 
the same subject, whenever possible. Note: truncal lesions counts will not be performed for subjects 
participating in truncal acne treatment. 
Inflammatory lesions are defined as follows: 
Papule:  An erythematous, raised, palpable lesion less than 5 mm in diameter 
Pustule: An erythematous, raised, likely palpable lesion containing white exudate or pus less than 5 mm in   
              diameter 
Nodule: A deep-seated, erythematous, firm lesion greater than 5 mm in diameter 
Non-inflammatory lesions are defined as follows: 
Open comedone (blackhead):   A widely dilated sebaceous follicle plugged with darkly pigmented sebum 
Closed comedone (whitehead): A small, closed sebaceous follicle distended with sebum, with a white   
                                                   appearance 
Evaluator’s Global Severity Score (EGSS) 
At each visit, the severity will be determined based on evaluator-blinded evaluations of the signs and 
symptoms of acne vulgaris. Every effort should be made to have the same evaluator assess the same 
subject at each visit. If this is not possible, the same evaluator should assess the subject at both the 
Baseline and Week 12 visits. Evaluations of the face will be scored on a scale of 0-4, with 0 being clear 
and 4 being severe. Please see the table below for complete definitions. The EGSS should always be 
completed prior to the lesion counts. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
9 
 
 
Score 
Grade 
Description 
0 
Clear 
Normal, clear skin with no evidence of acne vulgaris 
1 
Almost clear 
Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must 
be resolving and may be hyperpigmented, though not pink-red) 
2 
Mild 
Some non-inflammatory lesions are present, with few inflammatory lesions 
(papules/pustules only; no nodulocystic lesions) 
3 
Moderate 
Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be 
1 nodulocystic lesion 
4 
Severe 
Inflammatory lesions are more apparent, many comedones and papules/pustules, there 
may or may not be up to 2 nodulocystic lesions 
 
Truncal Severity Score (TSS) 
For any subjects participating in the treatment of truncal acne (optional), Investigators will use the TSS 
scale below to grade truncal acne at each visit (starting at Baseline), recording the score as a separate score 
from the facial EGSS acne score on a separate TSS form. 
Score 
Grade 
Description 
0 
Clear 
Normal, clear skin with no evidence of acne vulgaris 
1 
Almost clear 
Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must 
be resolving and may be hyperpigmented, though not pink-red) 
2 
Mild 
Some non-inflammatory lesions are present, with few inflammatory lesions 
(papules/pustules only; no nodulocystic lesions) 
3 
Moderate 
Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be 
1 nodulocystic lesion 
4 
Severe 
Inflammatory lesions are more apparent, many comedones and papules/pustules, there 
may or may not be up to 2 nodulocystic lesions 
 
Safety Measurements: 
Safety evaluations will include the following: 
- 
The percent of subjects who experience a cutaneous reaction (erythema, scaling, 
hypo/hyper-pigmentation, itching, burning, or stinging) graded at a level of 3 at any point in the 
study following the first application of study drug. 
- 
The percent of subjects who experience a cutaneous adverse event (AE) irrespective of severity 
grade at any point in the study following the first application of study drug. 
- 
Changes from baseline in all safety laboratory values and vital sign measurements as summarized 
using descriptive statistics by treatment group and study visit. 
- 
Subjects will be assessed for the occurrence of new and ongoing AEs.  
Cutaneous safety and tolerability will be evaluated by tabulations of AEs and Cutaneous Safety and 
Tolerability Evaluation scores (scaling, erythema, hypo/hyper-pigmentation, itching, burning, and 
stinging) to be assessed at each study visit.  Itching, burning and stinging (cutaneous tolerability) will be 
reviewed with the subject at each study visit as an average over the period since the previous visit. 
Scaling, erythema, and hypo/hyper-pigmentation (cutaneous safety) will be assessed by the evaluator at 
each visit. Cutaneous tolerability signs and symptoms that result in the subject requiring a concomitant 
therapy, interruption of treatment, or discontinuation from the study will be reported as an AE. 
Statistical Methods 
All statistical processing will be performed using SAS® version 9.4 or later unless otherwise stated.   
Statistical significance for superiority analyses will be based on two-tailed tests of the null hypothesis 
resulting in p-values of 0.05 or less. 
Non-inferiority of IDP-126 Gel to Epiduo® Forte will be assessed with 95% confidence intervals with the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
10 
 
following non-inferiority margins: 
1) Absolute change from Baseline to Week 12 in inflammatory lesion counts: 2.1 
2) Absolute change from Baseline to Week 12 in non-inflammatory lesion counts: 2.1 
3) Percentage of subjects who achieve at least a two-grade reduction from baseline and are “Clear” 
or “Almost Clear” at Week 12 in the Evaluator’s Global Severity Score: 10% 
Confidence intervals and superiority testing of lesion counts will be based on an ANCOVA with factors of 
treatment and analysis center and the respective Baseline lesion count as a covariate.  
Confidence intervals and superiority testing of the dichotomized EGSS will be based on logistic 
regression with factors of treatment group and analysis center. The TSS will be recorded for applicable 
subjects with truncal acne, and will be summarized at Week 2, 4, 8, and 12, with the percentage of 
subjects achieving at least a 2-grade reduction from baseline included in the summary. 
The primary method of handling missing efficacy data will be based on estimation using the method of 
Markov Chain Monte Carlo (MCMC) imputation. Other methods, as well as the MCMC imputation, will 
be specified in the statistical analysis plan which will be finalized prior to data base lock. 
Populations Analyzed and Treatment Groups: 
Inflammatory and non-inflammatory lesion counts will be recorded for each Subject at Baseline and at 
Weeks 2, 4, 8, and 12. The absolute and percent change from Baseline in inflammatory and non-
inflammatory lesions will be derived for each Subject at Weeks 2, 4, 8, and 12.  
The EGSS will be recorded for each Subject. The EGSS will be dichotomized into “success” and “failure” 
with a subject considered a success if the Evaluator’s Global Severity Score at Week 2, 4, 8, and 12 is at 
least 2 grades less than baseline and Clear or Almost Clear. 
Populations Analyzed: 
An intent-to-treat (ITT) analysis will be conducted on all study subjects. The ITT population will consist 
of all randomized subjects who received study drug. 
All subjects who are randomized and receive at least 1 confirmed dose of study drug will be included in 
the Safety population. 
A per-protocol (PP) analysis will also be conducted. Subjects will be eligible for the PP analysis if they 
complete the 12-week evaluation without noteworthy study protocol violations (i.e., any subject or 
investigator activity that could have possibly interfered with the therapeutic administration of the 
treatment or the precise evaluation of treatment efficacy). The PP population will include subjects in the 
ITT population who do not meet any of the following criteria: 
• Failed any of the inclusion/exclusion criteria. 
• Have taken any interfering concomitant medications. 
• Did not attend the Week 12 visit, with the exception of a discontinuation from the study due to an AE 
related to study treatment or documented lack of treatment effect. 
• Missed more than 1 post baseline study visit prior to Week 12. 
• Have not been compliant with the dosing regimen (i.e., subjects may not miss more than 5 
consecutive days of dosing and must take 80%-120% of expected doses). The number of expected 
doses will be determined for each subject based on the length of their participation in the study. 
• Out of visit window at the Week 12 visit. 
Subjects who discontinue from the study due to an adverse event related to study treatment or documented 
lack of treatment effect (and/or worsening of condition) will be included in the PP population. Prior to 
breaking the blind, other additional criteria may be added to the list to accommodate for unforeseen events 
that occurred during the conduct of the trial that result in noteworthy study protocol violations.  
Approximately 660 subjects will be randomized in a 2:2:1:1 ratio to the following treatment groups: 
• 
220 Subjects to IDP-126 Gel (clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%) 
• 
220 Subjects to Epiduo® Forte Gel (adapalene 0.3%/BPO 2.5%) 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
11 
 
• 
110 Subjects to IDP-126 Vehicle Gel (stored at 2-8°C) 
• 
110 Subjects to IDP-126 Vehicle Gel (stored at controlled room temperature) 
Subject demographic and baseline characteristics will be summarized by treatment group using descriptive 
statistics for the ITT, PP, and Safety analysis sets. 
Efficacy Evaluation: 
Primary efficacy analyses will be conducted on the ITT (primary) and PP (supportive) populations.   
Secondary analyses will be conducted on the ITT population.  
Primary: 
Co-primary efficacy analyses include the absolute change from baseline in inflammatory and in non-
inflammatory lesions, and the dichotomized Evaluator’s Global Severity Score.  The pre-specified time 
point will be Week 12. All of the testing relating to the analysis of inflammatory and non-inflammatory 
lesions will use the methods introduced in Section 12. 
Secondary:  
Secondary efficacy endpoints include absolute and percent change in inflammatory and non-inflammatory 
lesion counts from baseline to Weeks 2, 4, 8, and 12 and also percentage of subjects with at least a two-
grade improvement and are “clear” to “almost clear” in the Evaluator’s Global Severity Score from 
baseline at each visit. 
For subjects with truncal acne, percentage of subjects who have at least a 2-grade reduction at Week 2, 4, 
8, 12 from Baseline in the TSS will be evaluated. 
Safety Evaluation: 
All subjects who are randomized and receive at least 1 confirmed dose of study drug will be included in 
the Safety population. Safety will be evaluated by tabulations of AEs, Cutaneous Safety and Tolerability 
Evaluations, vital signs/abbreviated physical examinations, and safety laboratory results.  
Cutaneous Safety and Tolerability Evaluation scores (erythema, scaling, hypo/hyper-pigmentation, 
itching, burning, and stinging) will be presented with descriptive statistics at baseline and at Weeks 2, 4, 8, 
and 12 for each treatment group. Frequencies and percentages for each outcome category will be included 
in these statistics. Mean values will be presented graphically by week and treatment group. 
Vital sign measurements, an abbreviated physical examination, and safety laboratory results will be 
conducted on all subjects at specified visits. For pre-menses females and FOCBP, urine pregnancy and 
serum pregnancy testing will occur at specified visits. Changes from baseline in safety laboratory values 
and vital sign measurements will be summarized with descriptive statistics for each treatment group at all 
applicable study visits. Shift tables will be presented for changes in safety laboratory values to summarize 
laboratory test results collected at Baseline and Week 12. Normal ranges established by the central 
laboratory will be used to determine the shifts. A listing of all out-of-range laboratory test results at any 
assessment time point will also be provided.  
Determination of clinical significance for all out-of-range laboratory values will be made by each 
investigator and included in the listing. In addition, a listing of all clinically significant laboratory test 
results will be provided.  
All previous and concomitant medications will be classified based on terminology from the World Health 
Organization Drug Dictionary. Previous therapies and concomitant medications data will be presented in 
the data listings. 
All AEs occurring during the study will be recorded and classified using the Medical Dictionary for 
Regulatory Activities (MedDRA) terminology. Descriptions of AEs will include the date of onset, the date 
the AE ended, the severity of the AE, the relationship to study drug, the action taken regarding study drug 
usage, the action taken to treat the AE, and the outcome. Adverse events will be summarized by treatment 
group and severity. Each subject will be counted only once within a system organ class or a preferred term 
by using the AEs with the highest severity within each category. 
Adverse events will be summarized by treatment group and relationship to study drug. Each subject will 
be counted only once within a system organ class or a preferred term by using the AEs with the greatest 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
12 
 
relationship within each category. 
Comparisons among treatment groups will be made by tabulating the frequency of subjects with one or 
more AEs (classified into MedDRA terms) during the study.  The Fisher’s Exact test will be used to 
compare the percentage of subjects in each treatment group who report any adverse event at a significance 
level of 0.05.  The specific system organ classes and preferred terms analyzed will be those that are 
reported by at least one percent of the subjects in either active treatment group. 
All information pertaining to AEs noted during the study will be listed by subject, detailing the verbatim 
descriptions given by the investigator, preferred term, system organ class, start date, stop date, severity, 
actions taken, and drug relatedness. The AE onset will also be shown relative (in number of days) to the 
day of initial dose of the randomized study drug. Serious adverse events (SAEs) will be tabulated by 
subject within treatment groups. In addition, a list of subjects who discontinued from the study and a list 
of subjects who experienced SAEs will also be provided. 
 
Subject Self-Assessments 
Subjects will be asked to complete an Acne-Specific Quality of Life Questionnaire during the study. The 
Investigator assessments (EGSS and lesion counts) will be conducted independently of this subject self-
assessment. Inferential statistical analysis will not be performed on the questionnaire; the subjective 
responses will be compared between treatment groups for trends. 
 
This study will be performed in compliance with Good Clinical Practice including the archiving of 
essential study documents. This protocol follows guidelines outlined by the International Conference for 
Harmonisation. All data furnished to the investigator and his/her staff, and all data obtained through this 
study, will be regarded as confidential and proprietary in nature and will not be disclosed to any third 
party, except for the United States Food and Drug Administration or other regulatory body, without 
written consent from the sponsor. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
13 
 
3 Table of Contents 
1 
TITLE PAGE ...........................................................................................................1 
2 
SYNOPSIS ...............................................................................................................5 
3 
TABLE OF CONTENTS .......................................................................................13 
4 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ........................17 
5 
INTRODUCTION .................................................................................................18 
6 
STUDY OBJECTIVES AND PURPOSE .............................................................20 
7 
INVESTIGATIONAL PLAN ................................................................................20 
7.1 
Overall Study Design and Plan: Description .............................................20 
8 
SELECTION AND WITHDRAWAL OF SUBJECTS .........................................23 
8.1 
Subject Inclusion Criteria ..........................................................................23 
8.2 
Subject Exclusion Criteria .........................................................................24 
8.3 
Subject Withdrawal Criteria ......................................................................25 
9 
TREATMENT PLAN ............................................................................................27 
9.1 
Methods of Assigning Subjects to Treatment Groups ...............................27 
9.2 
Randomization and Blinding .....................................................................27 
9.3 
Unblinding .................................................................................................27 
9.4 
Prior and Prohibited Concomitant Medication or Therapy........................28 
9.5 
Treatment Compliance ...............................................................................29 
9.6 
Protocol Deviations and Violations ...........................................................29 
10 
STUDY DRUG MATERIALS AND MANAGEMENT ......................................30 
10.1 
IDP-126 Gel, Epiduo® Forte Gel, and IDP-126 Vehicle Gel ....................30 
10.1.1 Packaging and Labeling .................................................................31 
10.1.2 Storage, Handling, and Disposal of Study Drug ............................32 
10.1.3 Administration ...............................................................................32 
10.2 
Study Drug Accountability ........................................................................34 
11 
STUDY PROCEDURES AND EVALUATIONS ................................................34 
11.1 
Schedule of Evaluations and Procedures ...................................................35 
11.1.1 Visit 1: Screening Visit (Day −35 to Day 0) .................................35 
11.1.2 Visit 2: Baseline Visit (Day 0) .......................................................36 
11.1.3 Visit 3: Week 2 (Day 14 ± 3 Days) Visit .......................................37 
11.1.4 Visit 4: Week 4 (Day 28 ± 3 Days) Visit .......................................38 
11.1.5 Visit 5: Week 8 (Day 56 ± 3 Days) Visit .......................................39 
11.1.6 Visit 6: Week 12 (Day 84 -3/+5 Days) Visit – End of Study Visit40 
11.2 
Evaluation of Efficacy ...............................................................................41 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
14 
 
11.2.1 Evaluator’s Global Severity Score (EGSS) and Truncal Severity 
Score (TSS) ....................................................................................41 
11.2.2 Lesion Counts ................................................................................42 
11.2.3 Other Assessments .........................................................................43 
11.3 
Evaluation of Safety ...................................................................................43 
11.3.1 Cutaneous Safety Evaluations........................................................43 
11.3.2 Tolerability Evaluations .................................................................44 
11.3.3 Medical History and Abbreviated Physical Examination ..............44 
11.3.4 Laboratory Tests ............................................................................45 
11.3.5 Pregnancy Tests .............................................................................45 
11.4 
Adverse Events ..........................................................................................45 
11.4.1 Definition of Adverse Event ..........................................................45 
11.4.2 Documenting Adverse Experiences ...............................................45 
11.4.3 Serious Adverse Events .................................................................46 
11.4.4 Assessment of Severity ..................................................................47 
11.4.5 Assessment of Causality ................................................................47 
11.4.6 Reporting of Serious Adverse Events ............................................48 
11.4.7 Expedited Serious Adverse Event Reports ....................................49 
11.4.8 Pregnancy .......................................................................................49 
12 
STATISTICS .........................................................................................................50 
12.1 
Assessment of Efficacy ..............................................................................50 
12.1.1 Primary Efficacy ............................................................................51 
12.1.2 Secondary Efficacy ........................................................................51 
12.1.3 Non-Inferiority for Lesion Count Variables Evaluator's Global 
Severity Score ................................................................................51 
12.1.4 Test of Superiority for Lesion Count Variables Evaluator's Global 
Severity Score ................................................................................51 
12.1.5 Statistical Hypothesis Testing and Control of Multiplicity ...........52 
12.1.6 Descriptive Statistics ......................................................................53 
12.1.7 Missing Efficacy Data Imputations ...............................................53 
12.1.8 Subject Self-Assessments ..............................................................55 
12.2 
Assessment of Safety .................................................................................55 
12.2.1 Adverse Events ..............................................................................56 
12.2.2 Safety Laboratory Tests .................................................................56 
12.2.3 Vital Sign Measurements ...............................................................57 
12.2.4 Concomitant Medications ..............................................................57 
12.3 
Subject Disposition ....................................................................................57 
12.4 
Demographics and Baseline Characteristics ..............................................57 
12.5 
Protocol Deviations ....................................................................................57 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
15 
 
12.6 
Compliance ................................................................................................57 
12.7 
Interim Analyses ........................................................................................58 
12.8 
Additional Statistical Considerations .........................................................58 
12.8.1 Analysis Sets ..................................................................................58 
12.8.2 Sample Size Determination ............................................................59 
12.8.3 Handling of Missing Data ..............................................................60 
12.8.4 Multicenter Issues ..........................................................................60 
12.8.5 Multiplicity Issues ..........................................................................62 
12.8.6 Windowing Rules...........................................................................62 
13 
QUALITY CONTROL AND QUALITY ASSURANCE .....................................62 
13.1 
Study Monitoring .......................................................................................62 
13.2 
Audits and Inspections ...............................................................................62 
13.3 
Data Quality Assurance .............................................................................63 
14 
ETHICS AND ADMINISTRATIVE ISSUES ......................................................63 
14.1 
Ethical Conduct of the Study .....................................................................63 
14.2 
Ethics Review and Competent Authority Approval ..................................63 
14.3 
Written Informed Consent/Assent .............................................................63 
14.4 
Subject Data Protection..............................................................................64 
14.5 
Data Monitoring Committee ......................................................................64 
14.6 
Financial Disclosure ...................................................................................65 
14.7 
Finance .......................................................................................................65 
14.8 
Investigator Obligations .............................................................................65 
14.9 
Changes to the Protocol .............................................................................65 
14.10 Confidentiality/Publication of the Study ...................................................65 
15 
DATA HANDLING AND RECORD KEEPING .................................................65 
15.1 
Inspection of Records ................................................................................65 
15.2 
Retention of Records ..................................................................................66 
16 
REFERENCES ......................................................................................................67 
17 
APPENDICES .......................................................................................................69 
17.1 
Subject Instruction Sheet ...........................................................................69 
17.2 
Cleansers, Moisturizers and Sunscreen Use Guidelines ............................72 
17.3 
Acne-Specific Quality of Life Questionnaire (Acne-QoL) .......................73 
 
 
LIST OF TABLES 
Table 1. 
Study Design and Schedule of Assessments ..................................................22 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
16 
 
Table 2. 
Drug Substances Identification .......................................................................30 
Table 3. 
Study Drug Identification  ..............................................................................31 
Table 4. 
Evaluator’s Global Severity Score – Face ......................................................41 
Table 5. 
Truncal Severity Score (TSS) – Neck, Upper Chest, Upper Back & 
Shoulders ........................................................................................................41 
 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
17 
 
4 List of Abbreviations and Definitions of Terms 
Abbreviation or Specialist Term 
Definition or Explanation 
AE 
Adverse event 
BPO 
Benzoyl peroxide 
CBC 
cGCP 
Complete Blood Count 
Current Good Clinical Practice 
CRA 
Clinical Research Associate 
CRF 
Case Report Form 
CRO 
Contract Research Organization 
CRT 
eCRF 
Controlled Room Temperature 
Electronic case report form 
EGSS 
Evaluator’s Global Severity Score 
ET 
Early termination 
EudraCT 
European Union Drug Regulating Authorities Clinical Trials 
Database 
FDA 
United States Food and Drug Administration 
FOCBP 
Female of Childbearing Potential  
G 
Gram 
GCP 
Good Clinical Practice 
ICH 
International Conference for Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat  
LED 
Light Emitting Diode 
MedDRA 
Medical Dictionary for Regulatory Affairs 
OTC 
Over-the-counter 
PDT 
Photodynamic Therapy 
PP 
Per protocol 
QoL 
Quality of Life 
RTSM 
Randomization Trial Supply Management 
SAE 
Serious adverse event 
TSS 
UPT 
Truncal Severity Score  
Urine Pregnancy Test 
WHO 
World Health Organization 
 
 
 
In this protocol, “sponsor duties” refer to responsibilities that will be performed by the 
sponsor, the sponsor’s designee, or the sponsor’s designated contract research organization 
(CRO). In this protocol, “investigator” refers to the principal investigator or his/her designee, 
who is responsible for performing the study procedures and assessments. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
18 
 
5 Introduction 
Acne is a very common disorder of sebaceous follicles that is most prevalent among 
teenagers, usually triggered by the increase in androgen production occurring at puberty 
(Krakowski 2008). Although acne generally resolves by the age of 25, approximately 3% to 
8% of adults 25 to 44 years of age present with acne (Goodman 2006, White 1998). The 
pathogenesis is complex and appears to involve 4 primary features: stimulation of sebum 
gland activity, bacterial proliferation (especially Propionibacterium acnes), abnormal 
follicular hyperkeratinization and resultant obstruction of the sebaceous follicles, and the 
release of inflammatory mediators (Thiboutot 2009). These changes in acne patients result in 
the formation of clinical inflammatory lesions including superficial pustules such as 
comedones (popularly known as “blackheads” or “whiteheads”) and more deeply located 
papules, nodules, and cysts (Krakowski 2008). The areas most affected by the disease include 
the pilosebaceous follicles of the head and upper trunk, where the sebaceous glands are 
particularly active (Webster 2002). 
Given the complexity of the pathogenic mechanisms that lead to acne, for maximum 
efficacy, consensus guidelines recommend the use of combination therapy consisting of 
medications with different, but complementary, mechanisms of action (Thiboutot 2009). In 
particular, the guidelines advocate the use of a retinoid and an antibiotic (eg, clindamycin 
phosphate) or antibacterial (eg, benzoyl peroxide [BPO]) as first-line and maintenance 
therapy in patients with both inflammatory and non-inflammatory lesions (Ghali 2009, 
Thiboutot 2009).  
Although antibiotics like clindamycin were among the first effective treatments for acne, 
recent acne management guidelines discourage the use of antibiotics as monotherapy due to 
the development of bacterial resistance (Nast 2012, Thiboutot 2009). The guidelines also 
recommend limiting both the frequency and duration of antibiotic use for acne, and to use 
antibiotics in conjunction with BPO to minimize the development of resistance at sites of 
application (Thiboutot 2009). Topically applied BPO is keratolytic, comedolytic, and 
anti-inflammatory, and has bactericidal activity against Propionibacterium acnes (Gollnick 
2003, Harper 2010, Tanghetti 2009). To date, there is no evidence of P acnes resistance to 
BPO (Harper 2010). Further, the combination of BPO with chemical structures that contain a 
tertiary amine within their structure, such as clindamycin, increases the generation of BPO 
radicals and thereby creates a real biologic synergism (Burkhart 2008) that contributes to 
their complementary effects on acne pathogenesis. 
Retinoids (eg, adapalene, tretinoin, tazarotene) are anticomedogenic, anti-inflammatory, and 
inhibit microcomedone formation (Ghali 2009, Zaenglein 2008). Topical, daily retinoid 
monotherapy is used to inhibit the formation of comedones and usually clear even severe 
comedonal acne within a few months (Shalita 2001). Adapalene, a synthetic retinoid, is a 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
19 
 
naphthoic acid derivative with retinoid-like properties. In the cell, adapalene can bind 
specifically to retinoic acid nuclear (and not cytosolic) receptors to exert its effects 
(Zaenglein 2008). Biochemical and pharmacological profile studies have demonstrated that 
adapalene is a modulator of cellular differentiation, keratinization, and inflammatory 
processes (Piskin 2007). Topical formulations of adapalene have been used to treat acne in 
the United States (US) for more than 20 years. 
Retinoids have also been paired with antibiotic/BPO fixed-dose combination products 
(Bowman 2005, Del Rosso 2007, Kircik 2007, Tanghetti 2006) and, consistently across 
studies of these products, regimens that included a topical retinoid were more effective than 
regimens that did not (Thiboutot 2009). Adapalene (0.1% gel and cream formulations) has a 
lower irritation potential relative to other retinoids (Dosik 2005a, Dosik 2005b) and is 
therefore well suited for use in combination topical regimens, particularly those containing 
BPO, which is also potentially irritating (Del Rosso 2007).  
Thus, treatment with a combination of topical clindamycin phosphate, BPO, and adapalene 
can be expected to provide optimal overlapping benefits for maximal efficacy: each of these 
agents has some degree of anti-inflammatory activity; both the antibiotic and BPO decrease 
P acnes proliferation (Weiss 2004); BPO is also keratolytic (Harper 2010); and adapalene 
additionally regulates keratinization (Zaenglein 2008).  
A fixed-dose combination treatment is optimal to enhance patient adherence due to 
simplified application regimens (eg, once daily versus sequential morning/evening 
administration of each active agent) and also to preclude substance incompatibilities due to 
application errors (eg, oxidation by using incompatible single agents) (Thielitz 2013). Of 
note, when an adapalene 0.1% gel and a clindamycin 1.2%/BPO 5% fixed-dose combination 
gel were combined in equal amounts by weight, there was no resultant instability of any of 
the active components for up to 24 hours (Bikowski 2006).  
The current study is intended to evaluate the safety and efficacy of IDP-126 Gel, a novel 
fixed-dose combination of clindamycin phosphate, BPO, and adapalene (1.2%/3.1%/0.15%), 
relative to Epiduo® Forte Gel (0.3% adapalene / 2.5% BPO) and its vehicle (IDP-126 Vehicle 
Gel) for the treatment of acne vulgaris in subjects 12 years of age and older. 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
20 
 
6 Study Objectives and Purpose  
The objective of this study is to establish a clinical bridge for IDP-126 Gel to the comparator 
drug Epiduo® Forte Gel in subjects with moderate to severe acne vulgaris. The safety and 
efficacy of once daily application of IDP-126 Gel will be compared to Epiduo® Forte and 
IDP-126 Vehicle Gel.  
7 Investigational Plan 
7.1 
Overall Study Design and Plan: Description 
This is a multicenter, randomized, double-blind, vehicle-controlled, study designed to assess 
the safety, tolerability, and efficacy of IDP-126 Gel (clindamycin phosphate 1.2%/BPO 
3.1%/adapalene 0.15%) in comparison with Epiduo® Forte Gel (adapalene 0.3%/BPO 2.5%) 
and vehicle gel. To be eligible for the study, subjects must be at least 12 years of age or 
older, and have a clinical diagnosis of moderate to severe acne vulgaris (a score of 3 or 4 
[moderate to severe] on the Evaluator’s Global Severity Scale [EGSS]), presenting with 30-
100 inflammatory facial lesions (papules, pustules, and nodules), 35-150 non-inflammatory 
facial lesions (open and closed comedones), and ≤ 2 facial nodules.  
Approximately 660 subjects will be enrolled into this study and randomized into 1 of the 
following treatment groups in a 2:2:1:1 ratio:  
• 220 subjects to receive IDP-126 Gel, once daily application 
• 220 subjects to receive Epiduo® Forte Gel, once daily application 
• 110 subjects to receive IDP-126 Vehicle Gel (stored at 2-8°C), once daily 
application 
• 110 subjects to receive IDP-126 Vehicle Gel (stored at CRT), once daily 
application 
Subjects will be enrolled at approximately 40 independent study centers. The duration of 
treatment will be 12 weeks. Subjects will be evaluated at Screening, Baseline, and at 
subsequent follow-up visits (Weeks 2, 4, 8, and 12). 
A randomization trial supply management system (RTSM) will be employed to facilitate 
randomization of study subjects. Treatment assignments and study drug kit numbers will be 
generated centrally by the RTSM. At each study center, subject numbers will be assigned 
consecutively at the Screening visit, starting with 001. 
The assigned study drug will be applied topically to the face once daily at home, in the 
evening, for 12 weeks (up to the evening prior to the Week 12 visit), with the exception of 
study visit days (Baseline, Week 2, 4 and 8) where study drug will be applied (also by the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
CONFIDENTIAL 
21 
 
subject) after the study visit is completed, at the investigational center. The initial application 
will be done at the investigational center as per instruction from the study coordinator or 
designee. The subjects will be instructed to avoid exposure to direct sunlight in order to 
prevent sunburn. Use of sunscreens with at least a sun protection factor (SPF) of 15 and 
protective clothing (eg, a hat) is recommended when exposure cannot be avoided. Subjects 
will apply their daily treatments at home as explained by the study coordinator or designee at 
each study center. During post baseline study visits (Weeks 2, 4, 8 and 12), the subjects will 
be asked to return their used pumps of study drug and will be dispensed new pumps of study 
drug (new pumps dispensed on Weeks 4 and 8 only; Week 2 will have no new study drug 
dispensed; and Week 12 will be final visit). During the study, each subject will only be 
permitted to use approved, non-medicated cleansers, moisturizers, and sunscreens. 
Though not a requirement for study inclusion, the subject may be assessed for truncal acne 
(neck, upper chest, upper back and shoulders). If the subject presents with truncal acne and 
would like to apply study drug to these area(s), a separate evaluation will be performed to 
assess truncal acne using a Truncal Severity Score (TSS). TSS will be conducted at Baseline, 
Week 2, Week 4, Week 8, and Week 12. Subject participation in treatment of truncal acne is 
optional. 
During the study, subjects will be asked to complete the Acne-Specific Quality of Life 
questionnaire (Acne-QoL, Appendix 17.3). The Investigator assessments (EGSS, lesion 
counts, and TSS as applicable) will be conducted independently of this subject self-
assessment. The EGSS should be completed prior to the lesion counts. For subjects 
participating in the treatment of truncal acne, Investigators will only conduct the TSS, and 
lesions counts will not be conducted for truncal acne participants.   
The Acne-QoL questionnaire will be completed at Baseline and Week 12. Inferential 
statistical analyses will not be performed on the questionnaire; the subjective responses will 
be compared between treatment groups for trends. Information on reported and observed 
adverse events (AEs) will be obtained at each visit. An abbreviated physical examination, 
along with vital sign measurements, will be performed at Baseline and Week 12 (end of 
study, final visit) for all subjects. 
Blood samples will be collected from subjects at Baseline and Week 12 for CBC/Diff and 
serum chemistry.  For all female subjects of childbearing potential (FOCBP), urine 
pregnancy testing will be performed at Screening, confirmed prior to randomization at 
Baseline, and then repeated at Weeks 2, 4, 8 and 12. Serum pregnancy test will also be 
conducted at Baseline and Week 12. 
Subjects who terminate their study participation early will be asked to complete all Week 12 
assessments, as appropriate. Subjects who discontinue from the study during the treatment 
period will not be replaced. 

Protocol V01-126A-202 
 
          
 
 
Bausch Health 
 
 
Version 2.0, 2 March 2021 
 
 
 
 
 
 
CONFIDENTIAL 
22 
 
Table 1. 
Study Design and Schedule of Assessments 
PROCEDURES 
VISIT 1a 
Screening Visit 
(Day -35 to 0) 
VISIT 2 
Baseline 
Day 0 
VISIT 3 
Week 2 
(Day 14 ±3 days) 
VISIT 4 
Week 4 
(Day 28 ±3 days) 
VISIT 5 
Week 8 
(Day 56 ± 3 days) 
VISIT 6b 
Week 12  
(Day 84 -3/+5 days) 
Informed Consent/Assent 
X 
 
 
 
 
 
Obtain Subject Number from RTSM 
X 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
Medical Historyc 
X 
X 
 
 
 
 
Inclusion/Exclusion Criteriac 
X 
X 
 
 
 
 
Previous Therapiesc 
X 
X 
 
 
 
 
Acne-QoL 
 
X 
 
 
 
X 
Pregnancy Test (pre-menses and FOCBP)d 
X 
X 
X 
X 
X 
X 
Abbreviated Physical Examinationc,e 
X 
X 
 
 
 
X 
Vital Sign Measurementsc  
X 
X 
 
 
 
X 
Safety Labs (CBC/Diff, serum chemistry) 
 
X 
 
 
 
X 
EGSS 
X 
X 
X 
X 
X 
X 
Lesion Counts 
X 
X 
X 
X 
X 
X 
TSS (if applicable) 
 
X 
X 
X 
X 
X 
Photographs (select study centers only, face only) 
 
X 
 
X 
X 
X 
Cutaneous Safety Evaluationf 
 
X 
X 
X 
X 
X 
Tolerability Evaluationf 
 
X 
X 
X 
X 
X 
Randomization in RTSM (obtain kit #) 
 
X 
 
X 
X 
 
Administer Subject Instructions (see Appendix 17.1) 
 
X 
 
 
 
 
Dispense Study Drug  
 
X 
 
X 
X 
 
Weigh Study Drug  
 
X 
X 
X 
X 
X 
Study Drug Applied at Study Center 
 
X 
X 
X 
X 
 
Study Drug Collected 
 
 
 
X 
X 
X 
Subject Diary Calendar Dispensed 
 
X 
X 
X 
X 
 
Subject Compliance Reviewed / Diary Reviewed 
 
 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
Concomitant & Prohibited Therapies/Medication Review  
X 
X 
X 
X 
X 
X 
End of Study 
 
 
 
 
 
X 
a If no washout is needed, Visits 1 and 2 may occur on the same day. If a washout is needed, Visit 2 must occur after the appropriate washout period.  
b All Week 12 procedures must be completed for all subjects who terminate early. 
c Update at Baseline visit prior to randomization.  
d For pre-menses females and FOCBP, the urine pregnancy test must be completed at all scheduled visits. Serum pregnancy testing will be completed at Baseline and Week 12 only. Subjects with a positive pregnancy test 
at any time during the study will be discontinued.  
e Height will be measured at Screening only; weight measurements and examinations of other abbreviated physical parameters will be performed at Baseline and Week 12. 
f Cutaneous safety and tolerability will also be conducted (and recorded) for subjects participating in optional truncal acne application during the course of the study.

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
23 
8 Selection and Withdrawal of Subjects 
8.1 
Subject Inclusion Criteria 
Subjects meeting all of the following criteria will be eligible for study entry: 
1. Male or female at least 12 years of age and older. 
2. Written and verbal informed consent must be obtained. Subjects less than age of 
consent must sign an assent for the study and a parent or a legal guardian must sign 
the informed consent (if subject reaches age of consent during the study they should 
be re-consented at the next study visit). 
3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit. 
4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) 
count no less than 30, but no more than 100. 
5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) 
count no less than 35, but no more than 150. 
6. Subjects with 2 or fewer facial nodules. 
7. FOCBP1 and females who are premenses must be willing to practice effective 
contraception for the duration of the study. (Effective contraception is defined as 
stabilized on oral [either combined estrogen and progestogen containing or 
progestogen only] contraceptive for at least 3 months, intrauterine device/system, 
condom with spermicide, diaphragm with spermicide, implant, NuvaRing®, injection, 
transdermal patch, bilateral occlusion, vasectomized partner, or abstinence.) Females 
on birth control pills must have taken the same type pill for at least 3 months prior to 
entering the study and must not change type during the study. Those who have used 
birth control pills in the past must have discontinued usage at least 3 months prior to 
the start of the study. Women who use birth control for acne control only should be 
excluded. 
8. Premenses females and FOCBP must have a negative urine pregnancy test2 at the 
Screening Visit, and a negative urine pregnancy test at the Baseline Visit.  
9. Subjects must be willing to comply with study instructions and return to the clinic for 
required visits. Subjects under the age of consent must be accompanied by the parent 
or legal guardian at the time of assent/consent signing. 
10. If a cleanser, moisturizer or sunscreen is needed during the study, subjects must be 
willing to use only allowed cleansers, moisturizers, sunscreens, or 
moisturizer/sunscreen combination products (see Appendix 17.2). The subject must 
agree to use non-comedogenic products (including makeup and shaving products).  
 
1 Premenses females and FOCBP include any female who has not undergone successful surgical sterilization 
(hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea 
> 12 consecutive months; or women on hormone replacement therapy with documented plasma follicle-stimulating 
hormone level > 35mLU/mL). Even women who are using oral, implanted or, injectable contraceptive hormones, an 
intrauterine device, barrier methods (diaphragm, condoms, spermicidal) to prevent pregnancy, practicing abstinence 
or where partner is sterile (eg, vasectomy), should be considered to be of child bearing potential.           
2   Urine pregnancy tests must have a minimum sensitivity of 25mIU HCG/mL of urine and must be performed 
within 72 hours prior to the start of study drug. Kits will be provided by the CRO/designee. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
24 
8.2 
Subject Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from the study: 
1. Use of an investigational drug or device within 30 days of enrollment or participation 
in a research study concurrent with this study. 
2. Any dermatological conditions on the face that could interfere with clinical 
evaluations such as acne conglobata, acne fulminans, secondary acne, perioral 
dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, 
eczema. 
3. Any underlying disease(s) or some other dermatological condition of the face that 
requires the use of interfering topical or systemic therapy or makes evaluations and 
lesion count inconclusive. 
4. Subjects with a facial beard or mustache that could interfere with the study 
assessments. 
5. Subjects with more than two (2) facial nodules. 
6. Evidence or history of cosmetic-related acne. 
7. Subject has a history of experiencing significant burning or stinging when applying 
any facial treatment (eg, makeup, soap, masks, washes, sunscreens, etc) to their face. 
8. Female subjects who are pregnant, nursing mothers, planning a pregnancy during the 
course of the study, or become pregnant during the study. 
9. Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 
12 weeks immediately preceding study entry; subjects treated with estrogens 12 or 
more consecutive weeks immediately prior to study entry need not be excluded unless 
the subject expects to change dose, drug or discontinue estrogen use during the study. 
10. If female, subject has a history of hirsutism, polycystic ovarian disease or clinically 
significant menstrual irregularities. 
11. History of regional enteritis, ulcerative colitis, inflammatory bowel disease, 
pseudomembranous colitis, chronic or recurrent diarrhea, or antibiotic-associated 
colitis.  
12. Treatment of any type of cancer within the last 6 months, with the exception of 
complete surgical excision of skin cancer outside the treatment area.  
13. Subject uses medications and/or vitamins during the study which are reported to 
exacerbate acne (azathioprine, haloperidol, Vitamin D, Vitamin B12, halogens such 
as iodides or bromides, lithium, systemic or topical mid-to super-high potency 
corticosteroids on the treatment area, phenytoin and phenobarbital). Multivitamins, 
including Vitamin A, at recommended daily doses, and Vitamin D at stable doses, are 
acceptable. 
14. History of hypersensitivity or allergic reactions to any of the study preparations as 
described in the Investigator’s Brochure, including known sensitivities to any dosage 
form of clindamycin phosphate, BPO, or adapalene. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
25 
15. Concomitant use of potentially irritating over-the-counter products that contain 
ingredients such as BPO, alpha-hydroxy acid, salicylic acid, retinol or glycolic acids. 
16. Subjects who have not undergone the specified washout period(s) for the following 
topical preparations / physical treatments used on the face or subjects who require the 
concurrent use of any of the following in the treatment area: 
 
     
 
 
 
 
 
 
 
 
 
 
 
17. Subjects who have not undergone the specified washout period(s) for the following 
systemic medications or subjects who require the concurrent use of any of the 
following systemic medications: 
 
Corticosteroids (including intramuscular injections) 
    (inhaled corticosteroids are allowed)  
4 weeks 
Antibiotics 
4 weeks 
Other systemic acne treatments 
4 weeks 
Systemic retinoids 
6 months 
 
18. Subject intends to use a tanning booth or sunbathe during the study. 
19. Subjects who are unable to communicate or cooperate with the investigator due to 
language problems, poor mental development, or impaired cerebral function. 
20. Subjects with any underlying disease that the investigator deems uncontrolled, and 
poses a concern for the subject’s safety while participating in the study. 
8.3 
Subject Withdrawal Criteria 
Reasons for withdrawal may include, but are not limited to, the following: 
• Acne flare, as determined by the investigator, which requires treatment with a 
disallowed therapy. 
• Either at the investigator's request, for tolerability reasons (eg, severe adverse 
reactions), or at the subject’s request. 
• When the requirements of the protocol are not followed. 
Topical astringents and abrasives on the face 
1 week 
Non-allowed moisturizers or sunscreens on the face  
1 week 
Antibiotics on the face  
2 weeks 
Other topical anti-acne drugs on the face  
2 weeks 
Soaps containing antimicrobials on the face 
2 weeks 
Anti-inflammatory agents and corticosteroids on the face  
4 weeks 
Retinoids, including retinol on the face  
4 weeks 
Chemical peel/microdermabrasion on the face 
Light (e.g. LED, PDT) therapy on the face 
Acne surgery  
4 weeks 
4 weeks 
4 weeks 
Laser therapy on the face 
4 weeks 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
26 
• When a concomitant therapy likely to interfere with the results of the study is 
reported or required by the subject (the investigators will report all such information 
on the source documents/eCRFs and decide, in accordance with the Sponsor, whether 
the subject is to be withdrawn). 
• When a subject is lost to follow-up. The investigators will try twice to reach the 
subject by telephone, email and/or text message, and will send a follow-up letter by 
certified mail before considering that the subject is lost to follow-up. These actions 
will be reported on the End of Study source documents and the final eCRF and a copy 
of the follow-up letter will be maintained in the investigator’s file. 
All premature discontinuations and their associated reasons must be carefully documented by the 
investigator on source documents and the final eCRF, and, if need be, on the AE form. In any 
case, no subject who has been included and has an assigned study number can be replaced by 
another if the subject discontinues prematurely for whatever reason. All data gathered on the 
subject prior to termination will be made available to the Sponsor. 
Reasons for study completion/discontinuation as listed on the final report form are defined as 
follows: 
Normal Study Completion – Subject completes the study as planned in the protocol. 
Adverse Event – Complete an AE form. 
Death – Complete a serious adverse event (SAE) form. 
Subject Request – Consent withdrawal, subject moved, schedule conflicts. 
Protocol Violation – Contact the Sponsor or designee before making decision. 
Lost to Follow-Up – Document with 2 phone calls, emails and/or text messages, and a 
certified letter. 
Pregnancy – Subject will discontinue study drug immediately, but will be followed to term. 
Complete a pregnancy form. 
Worsening Condition – Subject requires alternate treatment for acne before the end of the 
study and the investigator determines it is not due to lack of efficacy. 
Lack of Efficacy – Subject requires alternate treatment for acne after at least 2 weeks of 
study drug treatment and the risk of continuing the subject in the study outweighs the benefit 
as determined by the investigator. 
Withdrawal by Parent/Guardian – An indication that the study participant has been 
removed from the study by the parent or legal guardian; includes consent withdrawal, subject 
moves, schedule conflicts, etc. 
Study Terminated by Sponsor – An indication that a clinical study was stopped by its 
Sponsor. 
Other – Specify in the comments section of the eCRF. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
27 
Subjects who terminate study drug early will be asked to complete all Week 12 assessments and 
procedures prior to commencement of any alternative therapy for acne (if possible). Subjects 
who discontinue from the study during the treatment period will not be replaced. 
All subjects are free to withdraw from participating in this study at any time and for whatever 
reason, specified or unspecified, and without prejudice. No constraints will be placed on ordinary 
subject management, and subjects, when appropriate, will be placed on other conventional 
therapy upon request or whenever clinically necessary as determined by their physician. 
9 Treatment Plan 
9.1 
Methods of Assigning Subjects to Treatment Groups 
This is a double-blind study in which the identity of the study drug will be unknown to the 
investigator/evaluator and all subjects, as well as all individuals closely associated with the 
study. 
Eligible subjects will be randomized to 1 of the 4 study drug groups in a ratio of 2:2:1:1 
(IDP-126 Gel : Epiduo® Forte Gel : IDP-126 Vehicle Gel (stored at 2-8°C) : IDP-126 Vehicle 
Gel (stored at CRT)).  
The study center will assign each screened subject a unique 6-digit study subject number. The 
number will consist of the 3-digit study center number (pre-assigned by Sponsor/designee) and 
the 3-digit chronological screening number, starting with 001 (eg, 101001, 101002). The 
randomization system will assign the study drug kit to subjects based on a randomization code; 
the kit will be dispensed to the subjects at Baseline and Weeks 4 and 8 by the study center staff. 
A study drug log will document the inventory, dispensing, and collecting of study drug at each 
study center. 
9.2 
Randomization and Blinding 
The study drugs will be packaged and labeled, and the study drug kits will be numbered 
sequentially and dispensed randomly to the subjects entering the study within each study center. 
Study drug supplies will be distributed to the study centers to maintain the randomization ratio 
within each study center.  
As a double-blind study, the investigators/evaluators, the study center staff, the Sponsor, and the 
clinical monitors will not be aware of the treatment assigned to the individual study subjects. 
Delegated staff members at each study center will dispense the study drugs and will collect all 
used and unused study drug pumps as scheduled. 
9.3 
Unblinding  
The treatment assignments for all enrolled subjects will be unblinded only after the conclusion of 
the study. Specifically, the blind will be broken only after all data are entered into the database, 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
28 
verified, and validated; subject evaluability assessments are performed and the database is 
locked. 
In the case of a medical emergency, the investigator can break the blind for the subject involved, 
preferably by first discussing the situation with the medical monitor and the Sponsor (or 
designee) immediately. After confirmation, the investigator will be contacted with unblinding 
information by a Sponsor representative or via the RTSM. The investigator will record the code 
break in the subject’s source documents. 
9.4 
Prior and Prohibited Concomitant Medication or Therapy 
Any concomitant medication or therapy stopped for washout as indicated below is to be 
recorded. As noted in the exclusion criteria, there are mandatory washout periods and restrictions 
during the study for the following topical treatments/physical treatments on the face that have a 
known beneficial effect for acne vulgaris: 
Topical astringents and abrasives on the face 
1 week 
Non-allowed moisturizers or sunscreens on the face 1 week 
Antibiotics on the face 
2 weeks 
Other topical anti-acne drugs on the face 
2 weeks 
Soaps containing antimicrobials on the face 
2 weeks 
Anti-inflammatory agents and corticosteroids on 
the face 
4 weeks 
Retinoids, including retinol on the face  
Chemical peel/microdermabrasion on the face 
Light (e.g. LED, PDT) therapy on the face 
Acne surgery 
Laser therapy on the face 
4 weeks 
4 weeks 
4 weeks 
4 weeks 
4 weeks 
 
 
In addition, there is a mandatory washout period and restriction on use during the study for the 
following systemic drugs: 
Corticosteroids (including intramuscular injections; 
inhaled corticosteroids are allowed) 
4 weeks 
Antibiotics 
4 weeks 
Other systemic acne treatments 
4 weeks 
Systemic retinoids 
6 months 
 
Subjects using concomitant therapies during the course of the study that could interfere with the 
interpretation of the study results (including, but not limited to, those listed above) should not be 
withdrawn, but the use of the concomitant product should be discontinued. Examples of 
products/procedures that are prohibited during the course of the study include (but not limited to) 
acne surgery, use of comedone removal strips, and use of comedogenic products (makeup, 
shaving products). With the exception of the study drug and the treatments listed above, no other 
topical/physical treatment for acne will be permitted. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
29 
Information on concomitant medications or therapies will be recorded in the Prior and 
Concomitant Medication or Therapy source document and eCRF. Any therapy used by the 
subject will be considered concomitant therapy (e.g., facial procedures, surgical procedures, 
investigations, and operations), and any medication, both over-the-counter (OTC) or 
prescription, used by the subject will be considered concomitant medication (eg, aspirin, Tylenol, 
birth control pills, vitamins). Every attempt should be made to keep concomitant medication / 
therapy dosing constant during the study. Any change to concomitant medication / therapy 
should be noted on the Concomitant Therapy or Medication source document and eCRF. 
All cleansers, moisturizers, sunscreens and other topical products used on the treatment area that 
are not medicated will be captured on the Prior and Concomitant Therapy source document and 
eCRF. Subjects must use investigator-approved, non-medicated cleansers, moisturizers, and 
sunscreens. 
Subjects should avoid excessive ultraviolet (UV) exposure by such activities as sunbathing or 
tanning booths. Use of sunscreens with at least SPF 15 and protective clothing during the day 
(eg, a hat) are recommended when exposure cannot be avoided.  
9.5 
Treatment Compliance 
Each subject will be instructed on the importance of returning his or her study drug at each 
applicable study visit. If a subject does not return his or her study drug at a particular study visit, 
he or she will be instructed to return it as soon as possible. The subjects will bring the pump(s) 
dispensed at each specified study visit to the next subsequent study visit. Each pump will be 
weighed on a calibrated scale (with the cap on, and to the nearest tenth of a gram) by a study 
coordinator or designee prior to dispensing and after collecting. The subject will also be asked to 
complete a diary calendar and will be questioned regarding study drug use since the previous 
visit in order to judge the subject’s compliance with applying the study drug. A subject who 
deviates meaningfully from the prescribed application amount will be counseled. Any missed 
applications of study drug will be noted by the subject on the diary, which will be collected and 
placed in the appropriate source document. Missed applications will be documented in the eCRF.  
9.6 
Protocol Deviations and Violations 
The investigators must read the protocol thoroughly and must follow the instructions exactly. 
A deviation from the protocol is an unintended and/or unanticipated departure from the 
procedures and/or processes approved by the Sponsor and the Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) and agreed to by the investigator. Deviations usually 
have an impact on individual subjects or a small group of subjects and do not involve 
inclusion/exclusion or primary endpoint criteria. 
A protocol violation occurs when there is non-adherence to the protocol that results in a 
substantial, additional risk to the subject, when the subject or investigator has failed to adhere to 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
30 
critical protocol requirements (eg, inclusion/exclusion criteria), or when there is non-adherence 
to FDA regulations, ICH GCP guidelines, and local regulatory requirements. 
Important protocol deviations impacting the safety of the subject or integrity of the study must be 
reported by the Investigator to the Sponsor, IRB/IEC, and regulatory authorities as applicable. 
Reporting of all other protocol deviations must adhere to the requirements of the governing 
IRB/IEC and regulatory authorities. 
The investigator or designee must document and explain in the subject’s source documentation 
any deviation from the approved protocol. The investigator may implement a deviation or 
protocol change to eliminate an immediate hazard to a study subject without prior IRB/IEC 
approval. As soon as possible after such an occurrence, the implemented deviation or change, the 
reasons for it, and any proposed protocol amendment(s) to prevent future occurrences, should be 
submitted to the IRB/IEC for review and approval, to the Sponsor for agreement, and to the 
regulatory authorities, if required. 
10 Study Drug Materials and Management 
The study drug will be dispensed by an appropriately qualified member of the study staff 
assigned by the investigator to this task. 
10.1 
IDP-126 Gel, Epiduo® Forte Gel, and IDP-126 Vehicle Gel 
The chemical names, chemical classes, and therapeutic classes of the active ingredients in 
IDP-126 Gel, Epiduo® Forte Gel and IDP-126 Vehicle Gel are listed in Table 2. Information 
regarding the study drugs is presented in Table 3.  
Table 2. 
Drug Substances Identification 
Established Name 
Clindamycin Phosphate 
Chemical Name 
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-
pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galactooctopyranoside 
2-(dihydrogen phosphate). 
Chemical Class 
Lincosamide antibiotic 
Therapeutic Class 
Anti-acne 
 
Established Name 
Benzoyl Peroxide 
Chemical Name 
Peroxide, Dibenzoyl 
Chemical Class 
Peroxide  
Therapeutic Class 
Anti-acne 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
31 
Established Name 
Adapalene 
Chemical Name 
(6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid) 
Chemical Class 
Synthetic retinoid 
Therapeutic Class 
Anti-acne 
 
 
Table 3. 
Study Drug Identification  
 
Investigational Products 
IDP-126 Gel 
IDP-126 Vehicle Gel-
Refrigerated 
Stored at 2-8 °C 
IDP-126 Vehicle Gel-
Room Temperature 
Stored at CRT 
(Controlled Room 
Temperature) 
Epiduo® Forte Gel 
Name of 
Active 
Ingredient 
Clindamycin 
phosphate, BPO, 
and adapalene, 
USP 
None 
None 
Adapalene and BPO, 
USP 
Drug Name / 
Formulation/ 
Concentration 
Clindamycin 
phosphate 
1.2%/BPO 3.1%/ 
adapalene 0.15%, 
Gel 
IDP-126 Vehicle Gel 
IDP-126 Vehicle Gel 
Adapalene 0.3% / 
BPO 2.5% 
Manufacturer 
 
Bausch Health Companies Inc. 
2150 St. Elzear Blvd West, Laval (Quebec), Canada H7L 4A8 
 Galderma  
Packaging 
White Pump with weight range between 45g and 50g 
Storage 
Requirements 
Store at 2-8 °C (36-46°F) prior to dispensing. 
Once dispensed, the product should be stored 
at room temperature up to 25°C (77°F) and 
assigned a 5-week use-by date. Do not freeze. 
Store at 20°–25°C (68°–77°F), with excursions 
permitted to 15° to 30°C (59° to 86°F). Once 
dispensed to the subject, assign a 5-week use-by 
date. Do not freeze.   
Appearance 
Opaque white to off-white gel 
Opaque white to very 
pale yellow gel 
Dosing 
Schedule 
Once daily × 12 weeks 
Route of 
Administration 
Topical Application 
 
10.1.1 Packaging and Labeling 
IDP-126 Gel, Epiduo® Forte Gel, and IDP-126 Vehicle Gel will be supplied in subject kits. The 
IDP-126 Vehicle Gel will be two separate treatment arms: one arm will be refrigerated and 
stored at 2-8°C (36-44°F) prior to dispensation and the other arm will be stored at Controlled 
Room Temperature (CRT). Instructions will be provided to the designated study drug technician 
at each study center. When a subject is randomized into the study, the RTSM-specified kit 
number will be assigned to be used for that randomized subject. Each subject kit will contain one 
pump, containing 45-50g of study material. One pump will be dispensed to the subject at each 
dispensing visit: Baseline, Week 4, and Week 8. Each pump will be weighed on a calibrated 
scale, prior to dispensing (with the cap on, and to the nearest tenth of a gram). After weighing the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
32 
pump and prior to first use of the study drug pump, the pump will need to be actuated 
approximately 10 times until the gel begins to dispense.  The pump is actuated by depressing the 
pump head using one or two fingers. This is to remove the air from the pump prior to product 
dispensing and is known as “priming the pump”. Priming the pump must occur at each 
dispensing visit (or if/when a replacement pump is issued).  
The subject will bring the pump to the next study visit (Week 2), where it will be collected and 
weighed (with the cap on, and to the nearest tenth of a gram) – a new pump will not be dispensed 
at this visit, and the original pump will be returned to the subject. The subject will then bring the 
same pump to the subsequent study visit (Week 4), where it will be collected and weighed (with 
the cap on) to the nearest 0.1 gram; one new pump will be dispensed again by the RTSM at 
Week 4, weighed (with the cap on) to the nearest 0.1 gram and provided to the subject. The same 
will occur at the Week 8 visit. If the subject loses a pump (lost or damaged pump), another kit 
will be dispensed via RTSM under an unscheduled visit. When weighing the subject’s returned 
pump, if the cap is missing, a cap should be borrowed from another pump for weighing purposes; 
after weighing the pump with the borrowed cap, the cap should be returned to its original pump. 
All used and unused study drug pumps will be collected and weighed at the final study visit 
(Week 12). All dispensing and collecting of study drug pumps will be documented on the study 
drug accountability log.  
Study drug will be packaged and labeled in a manner consistent with study design.  Study drug 
will be labeled according to applicable country and regional regulations for an investigational 
drug.    
10.1.2 Storage, Handling, and Disposal of Study Drug 
At the investigational center, the IDP-126 Gel and IDP-126 Vehicle Gel (Refrigerated) should be 
stored at 2°C to 8°C (36°F to 46°F) and should not be frozen. Once opened and dispensed to the 
subject, the study drug should be stored at room temperature up to 25°C (77°F).  Epiduo® Forte 
Gel and IDP-126 Vehicle Gel (Room Temperature) should be stored at 20°–25°C (68°–77°F), 
with excursions permitted to 15° to 30°C (59° to 86°F) and should not be frozen. Once opened 
and dispensed to the subject, assign a 5-week use-by date.   
Once a kit has been assigned to a subject, the kit should be pulled from pre-dispensing storage 
conditions, and kept in the secure drug storage area by an unblinded dispenser for approximately 
10 to 15 minutes before dispensing to the subject. All empty, partially used and unused study 
drug will be returned to the Sponsor or designee upon study completion of the study for 
documented disposal. 
10.1.3 Administration 
For all subjects, the study drug will be applied topically to the face once daily at home in the 
evening, at least 30 minutes before bedtime, for a period of 12 weeks, with the exception of 
study visit days (Baseline, Week 2, 4, and 8) where study drug will be applied by the subject 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
33 
after the study visit is completed at the investigational center. For the subset of subjects who will 
be treating truncal (neck, upper chest, upper back and shoulders) acne (optional), they should 
follow the same instructions as noted for the face.  The study drug will be applied as a thin 
coating that is gently rubbed into the skin. Study drug use will be limited to the face, and truncal 
areas (if applicable). 
The investigator and/or trained study center staff member will instruct the subject on the proper 
study drug application procedure during the Baseline visit (see Appendix 17.1). All subjects will 
be instructed to apply the study drug at approximately the same time every day for 12 weeks, 
after cleansing with an investigator-approved cleanser. On study visit days (Baseline, Weeks 2, 
4, and 8) subjects should be instructed to wait until the end of their study visit to apply study 
medication at the investigational site (note, this will affect evening application times on study 
visit days, which is acceptable. Subjects should not apply another dose of study drug in the 
evening on the study visit days). No time interval between dosing and meals or any other activity 
is specified. Study center personnel oversight of a subject’s on-site application of study drug is 
required at Baseline, Week 4 and Week 8, to ensure training/reinforcement of proper application 
technique.  
During daily application, subjects will be instructed to gently wash their faces with an 
investigator-approved, non-medicated cleanser and warm (not hot) water. After washing, the 
subjects will be asked to thoroughly rinse and gently pat their faces dry. The subjects should use 
the pump to dispense one pea size amount of the study drug onto the fingertip.  The study drug 
gel should be dotted onto 6 areas of the face: the chin, left cheek, right cheek, nose, left forehead, 
and right forehead. After distributing the gel in this manner, the subject should gently rub the gel 
into the skin. This amount of drug should be sufficient to cover the entire face excluding the 
mouth, eyes, inside the nose, and lips. It is important for the subject to treat their entire face 
(excluding the mouth, eyes and lips) and they should be instructed NOT to treat only specific 
lesions. The subjects should gently smooth the study drug over the face evenly. The study drug 
should become invisible almost immediately following application with gentle rubbing. If this 
does not happen, the investigator should instruct the subject on the use of a smaller dosage. The 
subject should wash his/her hands after applying the study drug to the face. Subjects should also 
be instructed to place the cap back onto the pump after every use. 
For subjects applying the study drug to the truncal area, the subjects or their designee 
(parent/legal guardian) will be instructed to cleanse the area gently before application of the 
study drug. The subjects should continue to use the pump to dispense one pea size amount onto 
the fingertip. The study drug should be spread in a thin layer across the truncal area (neck, upper 
chest, upper back and shoulders). It is important that the study drug is spread evenly, and specific 
lesions are not treated. The study drug should become invisible almost immediately following 
application with gentle rubbing. If this does not happen, the investigator should instruct the 
subject on the use of a smaller dosage. The subject should wash his/her hands after applying the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
34 
study drug. Subjects should also be instructed to place the cap back onto the pump after every 
use. 
At each study visit, study staff will review the subject instructions for application of study drug 
to ensure proper use and compliance with application. The subjects will be instructed to continue 
using the same investigator-approved, non-medicated facial cleanser, moisturizer, and sunscreen, 
and not to change products during the study. At each visit, subjects are to be asked if they have 
changed their cleansing routine. Facial makeup may be applied according to the subject’s normal 
daily routine; however, subjects should be instructed not to wear makeup during study visits as it 
may interfere with the evaluator’s assessments. Subjects must also agree to use non-
comedogenic makeup during the study if they use makeup. No other products should be used in 
the treatment area. Subjects should be instructed to minimize sun exposure and to use 
investigator-approved, non-medicated sunscreens of at least SPF 15 and to wear protective 
clothing during the day (eg, a hat) if exposure cannot be avoided.  
Subjects should be instructed to store the study drug at room temperature. If a subject loses or 
misplaces the pump cap at any point during the study, the subject should contact the study center 
to return the exposed pump and receive a replacement pump.  
10.2 
Study Drug Accountability 
Upon receipt of the study drug, the investigator is responsible for ensuring that the designated 
study center staff member will conduct a complete inventory of the study drugs and assume 
responsibility for their appropriate storage and dispensing. In accordance with federal 
regulations, the investigators must agree to keep all study drugs in a secure location with 
restricted access. The investigator will keep a record of the inventory, dispensing, and collecting 
of all study drugs. This record will be made available to the Sponsor’s monitor for the purpose of 
accounting for all study drugs. Any significant discrepancy and/or deficiency must be recorded 
with an explanation. 
All supplies sent to the investigators will be accounted for and, in no case, used in any 
unauthorized situation. Pumps will be weighed on a calibrated scale (with the cap on, and to the 
nearest tenth of a gram) before dispensing to and upon return by the subjects, and weights will be 
recorded on the pharmacy log and appropriate eCRF. All used and unused supplies will be 
returned to Sponsor/designee for destruction at the conclusion of the study. If a subject 
loses/misplaces a cap, the pump should still be weighed using a cap from another pump/kit.  
11 Study Procedures and Evaluations 
All subject information and data obtained during the study visits will be recorded in the source 
documents, applicable study logs, and eCRFs. 
Evaluators must have appropriate, documented experience and training, or obtain approval from 
the Sponsor based on experience (or through additional training organized by the Sponsor). 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
35 
At each study visit, every attempt should be made to ensure that the same investigator/evaluator 
assesses the same subject.  
11.1 
Schedule of Evaluations and Procedures 
11.1.1 Visit 1: Screening Visit (Day −35 to Day 0) 
The following procedures will be conducted at this visit: 
1. Obtain written informed consent prior to performing any study procedures. Subjects less 
than the age of consent must sign an assent form, and the parent or legal guardian must 
sign the informed consent form. 
2. Assign the subject a 6-digit subject number by accessing RTSM. The number will consist 
of the 3-digit study center number (pre-assigned to your study center) and the 3-digit 
sequential order screening number assigned by the RTSM (eg, 101001, 101002; in this 
example study center number is 101). 
3. Record the subject’s demographic information. 
4. Record the subject’s medical history. 
5. Record all previous medications (including acne medications) used for the past 4 weeks 
(past 6 months for systemic retinoids). Record any therapies that will be used 
concomitantly during the study.  
6. Perform an abbreviated physical examination, including height and weight, and measure 
vital signs (blood pressure, heart rate, respiration rate, and oral temperature). Note: height 
will only be measured at Screening, and not at subsequent study visits. 
7. Assess the subject using the EGSS, followed by inflammatory and non-inflammatory 
lesion counting to determine eligibility.  
8. Perform a urine pregnancy test for all females who are premenses and FOCBP. The urine 
pregnancy tests will be supplied by the CRO/designee.  
9. Verify that the subject meets the applicable inclusion/exclusion criteria as outlined in 
Sections 8.1 and 8.2.  
10. Discuss allowed cleansers, moisturizers, and sunscreens, and record any cleanser, 
moisturizer, and sunscreen use (Appendix 17.2). 
11. If subject wears makeup, remind the subject not to wear makeup during any future visits. 
12. If the subject requires a washout, schedule the Baseline visit to occur after the washout is 
complete. If no washout is required, the Screening and Baseline visits may occur on the 
same day.  
13. Schedule the subject to return for the Baseline/Day 0 visit. If the subject requires a 
washout, schedule the Baseline/Day 0 visit to occur after the washout is complete. 
NOTE: At the Baseline and Week 12 visits, serum pregnancy testing is mandatory for all pre-
menses females and FOCBP. A urine pregnancy test must be completed at all scheduled study 
visits. The decision may be made by the investigator to do additional pregnancy tests during the 
course of the study. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
36 
11.1.2 Visit 2: Baseline Visit (Day 0)  
If a washout is not needed, this visit may occur on the same day as the Screening Visit (Visit 1). 
If a washout is needed, Visit 2 (Baseline) must occur after the appropriate washout period based 
on the criteria provided in Section 8.2.  
The following procedures will be conducted at this visit: 
1. The baseline Acne-QoL questionnaire will be completed by the subject and collected 
prior to conducting any other study-related procedures.  
2. Verify that the subject continues to meet the applicable inclusion/exclusion criteria as 
outlined in Sections 8.1 and 8.2. 
3. Record any changes in medical history since screening. 
4. Record changes in any concomitant medications or therapies since the previous visit 
under Prior and Concomitant Medications or Therapies. Check for prior and concomitant 
medications / therapies as per Section 9.4. 
5. Perform a urine pregnancy test for all females who are premenses and FOCBP. The urine 
pregnancy tests will be supplied by the CRO/designee. 
6. Perform an abbreviated physical examination, including measurements of weight and 
vital signs (blood pressure, heart rate, respiration rate, and oral temperature). Any 
abnormal physical examination findings will be recorded. 
7. The evaluator will perform the Baseline efficacy evaluations including an assessment 
based on the EGSS, and counts of inflammatory and non-inflammatory lesions. The 
EGSS is performed prior to the lesion counting. Every effort should be made for the same 
qualified, validated evaluator to perform the efficacy evaluations at all visits from 
Baseline to Week 12 for the same subject.  
8. If the subject presents with truncal acne and agrees to have their study drug applied to 
these areas, then TSS will be performed from Baseline to Week 12. Note: lesion counts 
will not be performed for truncal acne. 
9. The evaluator will perform the Cutaneous Safety and Tolerability Evaluations. If the 
subject presents with truncal acne and agrees to have their study drug applied to these 
areas, then the Cutaneous Safety and Tolerability Evaluations will also be performed for 
these areas. 
10. Collect blood samples for routine laboratory analysis (CBC/Diff, serum chemistry, and 
serum pregnancy for pre-menses females and FOCBP). 
11. Select Sites Only – Obtain representative photographs of the face. 
12. Assign the subject the appropriate kit number (this number will be generated from the 
RTSM).  
13. Once a kit has been assigned to a subject, the kit should be pulled from pre-dispensing 
storage conditions, and kept in the secure drug storage area by an unblinded dispenser for 
approximately 10 to 15 minutes before dispensing to the subject. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
37 
14. The study coordinator or designee will weigh a pump from the assigned kit and dispense 
it to the subject. The pump will be weighed (with the cap on) using a calibrated scale. 
Record the weight of the pump to the nearest 0.1 g. A study diary calendar will also be 
dispensed and the subject will be instructed to bring it to all subsequent visits.  
15. The study coordinator or designee will instruct the subject on the proper application 
procedure for the study drug per Section 10.1.3, and will provide written subject use 
instructions to the subject (Appendix 17.1). For the first application, the subject will 
apply the study drug at the study center under the direction of the study coordinator or 
designee. The study drug should be applied after all clinical assessments. The study 
coordinator or designee will instruct the subjects to apply the study drug once daily at 
home at the same time of day, and will instruct the subject to use an investigator-
approved, non-medicated sunscreen of at least SPF 15, and to wear protective clothing 
during the day (eg, a hat) if exposure cannot be avoided.  
16. Record any AEs or changes in AEs since the screening visit and/or reported 
spontaneously by the subject. 
17. Schedule the next study visit at Week 2 (Day 14 ± 3 days). Remind the subject not to 
apply study drug on day of next study visit. 
NOTE: At the Baseline and Week 12 visits, serum pregnancy testing is mandatory for 
all pre-menses females and females of childbearing potential.  
11.1.3 Visit 3: Week 2 (Day 14 ± 3 Days) Visit 
The following procedures will be conducted at this visit (if a subject terminates early, all final 
visit [Week 12/Final Visit] procedures must be performed): 
1. The evaluator will perform the efficacy evaluations including the EGSS, inflammatory 
and non-inflammatory lesion counts. The EGSS is performed prior to the lesion counting. 
Every effort should be made for the same qualified and validated evaluator to perform the 
efficacy evaluations at all visits from Baseline to Week 12 for the same subject.  
2. For subjects who are applying study drug to truncal acne, the TSS will be performed. 
Note: lesion counts will not be performed for truncal acne. 
3. The evaluator will perform the Cutaneous Safety and Tolerability Evaluations. For 
subjects who are applying study drug to truncal acne, then the Cutaneous Safety and 
Tolerability Evaluations will also be performed for these areas. 
4. Record changes in any concomitant medications / therapies since the previous visit under 
Prior and Concomitant Medications or Therapies. Check for prior and concomitant 
medications / therapies as per Section 9.4. 
5. Record any new AEs reported spontaneously by the subject or changes in any ongoing 
AEs. 
6. Perform a urine pregnancy test for all females who are premenses and FOCBP. The urine 
pregnancy tests will be supplied by the CRO/designee. 
7. The study coordinator or designee will retrieve and weigh the used study drug pump. 
Record the weight of the pump (with the cap on) to the nearest 0.1 g. Note: a new pump 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
38 
will NOT be dispensed at this visit. The original pump will be re-dispensed back to the 
subject. 
8. The study diary calendar will be collected and reviewed for compliance. Any missed 
doses or deviations should be reported. A new study diary calendar will be dispensed. 
9. The study coordinator or designee will remind the subject of the proper technique for 
application of study drug (Section 10.1.3). At this visit, the subject will apply the study 
drug at the study center under the direction of the study coordinator or designee to 
confirm proper technique. Any necessary retraining can be completed. The study drug 
should be applied after all clinical assessments. The study coordinator or designee will 
remind the subjects to apply the study drug once daily at home in the evening up to the 
evening prior to the Week 12 visit (study drug will not be applied in the evening after this 
study visit). 
10. The study coordinator will instruct the subject to use a Sponsor/investigator-approved, 
non-medicated sunscreen of at least SPF 15, and to wear protective clothing during the 
day (eg, a hat) if exposure cannot be avoided. 
11. Schedule the next study visit at Week 4 (Day 28 ± 3 days). Remind the subject to not 
apply study drug on day of next study visit, prior to the clinic visit. 
11.1.4 Visit 4: Week 4 (Day 28 ± 3 Days) Visit 
The following procedures will be conducted at this visit (if a subject terminates early, all final 
visit [Week 12/Final Visit] procedures must be performed): 
1. The evaluator will perform the efficacy evaluations including the EGSS, inflammatory 
and non-inflammatory lesion counts. The EGSS is performed prior to the lesion counting. 
Every effort should be made for the same qualified and validated evaluator to perform the 
efficacy evaluations at all visits from Baseline to Week 12 for the same subject.  
2. For subjects who are applying study drug to truncal acne, the TSS will be performed. 
Note: lesion counts will not be performed for truncal acne. 
3. The evaluator will perform the Cutaneous Safety and Tolerability Evaluations. For 
subjects who are applying study drug to truncal acne, then the Cutaneous Safety and 
Tolerability Evaluations will also be performed for these areas. 
4. Record changes in any concomitant medications / therapies since the previous visit under 
Prior and Concomitant Medications or Therapies. Check for prior and concomitant 
medications / therapies as per Section 9.4. 
5. Record any new AEs reported spontaneously by the subject or changes in any ongoing 
AEs. 
6. Perform a urine pregnancy test for all females who are premenses and FOCBP. The urine 
pregnancy tests will be supplied by the CRO/designee. 
7. The study coordinator or designee will collect/retrieve and weigh the used study drug 
pump (with the cap on) to the nearest 0.1 g. Assign the subject a new kit number (i.e., the 
number that was generated by the RTSM). Once a kit has been assigned to a subject, the 
kit should be pulled from pre-dispensing storage conditions, and kept in the secure drug 
storage area by an unblinded dispenser for approximately 10 to 15 minutes before 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
39 
dispensing to the subject. The new pump will be weighed (with the cap on) using a 
calibrated scale. Record the weight of the pump to the nearest 0.1 g.  
8. The study diary calendar will be collected and reviewed for compliance. Any missed 
doses or deviations should be reported. A new study diary calendar will be dispensed.  
9. Select Sites Only – Obtain representative photographs of the face.  
10. The study coordinator or designee will remind the subject of the proper technique for 
application of the study drug (Section 10.1.3). At this visit, the subject will apply the 
study drug at the study center under the direction of the study coordinator or designee to 
confirm proper technique. Any necessary retraining can be completed. The study drug 
should be applied after all clinical assessments. The study coordinator or designee will 
remind the subjects to apply the study drug once daily at home in the evening up to 
evening prior to Week 12 visit (study drug will not be applied in the evening after this 
study visit). 
11. The study coordinator will instruct the subject to use a Sponsor/Investigator-approved, 
non-medicated sunscreen of at least SPF 15, and to wear protective clothing during the 
day (eg, a hat) if exposure cannot be avoided. 
12. Schedule the next study visit at Week 8 (Day 56 ± 3 days). Remind the subject to not 
apply study drug on day of next study visit, prior to the clinic visit. 
11.1.5 Visit 5: Week 8 (Day 56 ± 3 Days) Visit 
The following procedures will be conducted at this visit (if a subject terminates early, all final 
visit [Week 12/Final Visit] procedures must be performed): 
1. The evaluator will perform the efficacy evaluations including the EGSS, inflammatory 
and non-inflammatory lesion counts. The EGSS is performed prior to the lesion counting. 
Every effort should be made for the same qualified and validated evaluator to perform the 
efficacy evaluations at all visits from Baseline to Week 12 for the same subject.  
2. For subjects who are applying study drug to truncal acne, the TSS will be performed. 
Note: lesion counts will not be performed for truncal acne. 
3. The evaluator will perform the Cutaneous Safety and Tolerability Evaluations. For 
subjects who are applying study drug to truncal acne, then the Cutaneous Safety and 
Tolerability Evaluations will also be performed for these areas. 
4. Record changes in any concomitant medications / therapies since the previous visit under 
Prior and Concomitant Medications or Therapies. Check for prior and concomitant 
medications / therapies as per Section 9.4. 
5. Record any new AEs reported spontaneously by the subject or changes in any ongoing 
AEs. 
6. Perform a urine pregnancy test for all females who are premenses and FOCBP. The urine 
pregnancy tests will be supplied by the CRO/designee. 
7. The study coordinator or designee will collect/retrieve and weigh the used study drug 
pump (with the cap on) to the nearest 0.1 g. Assign the subject a new kit number (i.e., the 
number that was generated by the RTSM). Once a kit has been assigned to a subject, the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
40 
kit should be pulled from pre-dispensing storage conditions, and kept in the secure drug 
storage area by an unblinded dispenser for approximately 10 to 15 minutes before 
dispensing to the subject. The new pump will be weighed (with the cap on) using a 
calibrated scale. Record the weight of the pump to the nearest 0.1 g.  
8. The study diary calendar will be collected and reviewed for compliance. Any missed 
doses or deviations should be reported. A new study diary calendar will be dispensed.  
9. Select Sites Only – Obtain representative photographs of the face. 
10. The study coordinator or designee will remind the subject of the proper technique for 
application of the study drug (Section 10.1.3). At this visit, the subject will apply the 
study drug at the study center under the direction of the study coordinator or designee to 
confirm proper technique. Any necessary retraining can be completed. The study drug 
should be applied after all clinical assessments. The study coordinator or designee will 
remind the subjects to apply the study drug once daily at home in the evening up to 
evening prior to Week 12 study visit (study drug will not be applied in the evening after 
this study visit). 
11. The study coordinator will instruct the subject to use a Sponsor/Investigator approved, 
non-medicated sunscreen of at least SPF 15, and to wear protective clothing during the 
day (eg, a hat) if exposure cannot be avoided. 
12. Schedule the next study visit at Week 12 (Day 84 -3/+5 days). Remind the subject to not 
apply study drug on day of next study visit, prior to the clinic visit. 
11.1.6 Visit 6: Week 12 (Day 84 -3/+5 Days) Visit – End of Study Visit 
The following procedures will be conducted at this visit: 
1. The Acne-QoL questionnaire will be completed by the subject and collected prior to any 
other study related procedures. 
2. Perform an abbreviated physical examination, including measurements of weight and 
vital signs (blood pressure, heart rate, respiration rate, and oral temperature). Any 
abnormal physical examination findings will be recorded. 
3. The evaluator will perform the efficacy evaluations including the EGSS, inflammatory 
and non-inflammatory lesion counts. The EGSS is performed prior to the lesion counting. 
Every effort should be made for the same qualified and validated evaluator to perform the 
efficacy evaluations at all visits from Baseline to Week 12 for the same subject.  
4. For subjects who are applying study drug to truncal acne, the TSS will be performed. 
Note: lesion counts will not be performed for truncal acne. 
5. The evaluator will perform the Cutaneous Safety and Tolerability Evaluations. 
6. Record changes in any concomitant medications / therapies since the previous visit under 
Prior and Concomitant Medications or Therapies. Check for prior and concomitant 
medications / therapies as per Section 9.4. 
7. Record any new AEs reported spontaneously by the subject or changes in any ongoing 
AEs. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
41 
8. The study diary calendar will be collected and reviewed for compliance. Any missed 
doses or deviations should be reported. 
9. The study coordinator or designee will retrieve all study drug (pump[s]) from the subject 
and weigh the pump(s) using a calibrated scale. The weight of the pump(s) (with the cap 
on) should be recorded to the nearest 0.1 g. 
10. Perform a urine pregnancy test for all females who are premenses and FOCBP. The urine 
pregnancy tests will be supplied by the CRO/designee. 
11. Collect blood samples for routine laboratory analysis (CBC/Diff, serum chemistry, and 
serum pregnancy for all pre-menses females and FOCBP).  
12. Select Sites Only – Obtain representative photographs of the face. 
13. Exit the subject from the study and complete the end of study eCRFs. 
11.2 
Evaluation of Efficacy 
The determination of efficacy will be based on evaluator-blinded assessments of the signs and 
symptoms of acne vulgaris. Evaluators must be a board-certified/board-eligible dermatologist or 
have appropriate documented experience and training, and be present for formal study training 
and validation at the Investigator Meeting (and/or Site Initiation Visit), or obtain a waiver from 
the Sponsor based on experience (or through additional training organized by the Sponsor).  
The EGSS assessments and lesion counts will be performed at each study visit. The EGSS 
assessments will be collected before the lesion counts. All subject assessments will be performed 
by a trained and validated evaluator. Every effort should be made to have the same evaluator 
assess the same subject at each visit. If this is not possible, the same evaluator should assess the 
subject at both the Baseline and Week 12 visits. If applicable, a separate TSS assessment and 
score will be collected and recorded for truncal acne at all study visits, starting at Baseline. 
11.2.1 Evaluator’s Global Severity Score (EGSS) and Truncal Severity Score (TSS) 
The EGSS will be a static assessment that is independent of the baseline score. The investigator 
will make the assessment without referring to the baseline value. Every effort should be made for 
the same evaluator to perform each study assessment for the same study subject, for consistency 
in evaluations.  
Subjects are eligible if they have acne vulgaris with a global severity of 3 (moderate) or 
4 (severe) on the EGSS at the Baseline visit. The following scores will be used to describe the 
severity grade and subsequent score: 
Table 4. 
Evaluator’s Global Severity Score – Face  
Score 
Grade 
Description 
0 
Clear 
Normal, clear skin with no evidence of acne vulgaris 
1 
Almost 
Clear 
Rare non-inflammatory lesions present, with rare noninflamed papules (papules must be 
resolving and may be hyperpigmented, though not pink-red) 
2 
Mild 
Some non-inflammatory lesions are present, with few inflammatory lesions 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
42 
(papules/pustules only; no nodulocystic lesions) 
3 
Moderate 
Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be 1 
nodulocystic lesion 
4 
Severe 
Inflammatory lesions are more apparent, many comedones and papules/pustules, there may 
or may not be up to 2 nodulocystic lesions 
 
For any subjects participating in the optional treatment of truncal acne (neck, upper chest, upper 
back and shoulders), Investigators will use the TSS scale below to grade truncal acne at each 
visit (starting at Baseline), recording the score as a separate score from the facial EGSS acne 
score on a separate TSS form. 
 
Table 5. 
Truncal Severity Score (TSS) – Neck, Upper Chest, Upper Back & Shoulders 
Score 
Grade 
Description 
0 
Clear 
Normal, clear skin with no evidence of acne vulgaris 
1 
Almost 
Clear 
Rare non-inflammatory lesions present, with rare noninflamed papules (papules must be 
resolving and may be hyperpigmented, though not pink-red) 
2 
Mild 
Some non-inflammatory lesions are present, with few inflammatory lesions 
(papules/pustules only; no nodulocystic lesions) 
3 
Moderate 
Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be 1 
nodulocystic lesion 
4 
Severe 
Inflammatory lesions are more apparent, many comedones and papules/pustules, there may 
or may not be up to 2 nodulocystic lesions 
 
11.2.2 Lesion Counts 
The facial area lesion counts will be taken from the subject’s face (including the nose). The 
lesion count groups will be inflammatory and non-inflammatory. Facial inflammatory lesions 
(pustules, papules, and nodules) will be counted as follows: pustules and papules will be counted 
and recorded together, not separately; nodular lesions will be counted and recorded separately. 
Non-inflammatory lesions (open and closed comedones) will be counted and recorded together. 
The lesion counts will be collected at each visit and/or upon discontinuation.  Note: lesions 
counts will not be conducted for truncal acne subjects. The following are definitions of each 
lesion type counted: 
Inflammatory lesions are defined as follows: 
 
Papule: 
An erythematous, raised, palpable lesion less than 5 mm in diameter 
Pustule: 
An erythematous, raised, likely palpable lesion containing white exudate or pus less  
than 5 mm 
Nodule: A deep-seated, erythematous, firm lesion greater than 5 mm in diameter 
 
Non-inflammatory lesions are defined as follows: 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
43 
Open comedone (blackhead): 
A widely dilated sebaceous follicle plugged with darkly 
pigmented sebum 
Closed comedone (whitehead): 
A small, closed sebaceous follicle distended with sebum, with 
a white appearance  
11.2.3 Other Assessments 
Photography 
At select study centers, photographs of the face will be taken at Baseline and at Weeks 4, 8, and 
12. Only subjects who provide written photographic consent for facial photographs will be 
included in photography. Note: photographs of truncal acne (if applicable) will not be conducted. 
11.3 
Evaluation of Safety 
Safety assessments will be conducted at baseline and each subsequent study visit.  
11.3.1 Cutaneous Safety Evaluations 
Cutaneous safety will be evaluated through an assessment, conducted at the time of the study 
visit, of selected local signs (i.e., signs present at the study drug application site) that include the 
following: scaling, erythema, hypopigmentation, and hyperpigmentation. The evaluator will 
assess all cutaneous safety signs. For subjects treating (optional) truncal acne, cutaneous safety 
evaluations will also be conducted on this area throughout the course of the treatment/study, and 
recorded separately. 
Cutaneous safety signs that result in the subject’s requiring a concomitant therapy, interruption 
of treatment, or discontinuation from the study, will be reported as an AE.  
Scaling: 
0 – None  
No scaling  
1 – Mild 
 
Barely perceptible, fine scales present on limited areas of the face 
2 – Moderate Fine scale generalized to all areas of the face 
3 – Severe  
Scaling and peeling of skin over all areas of the face 
 
Erythema: 
0 – None  
No evidence of erythema present  
1 – Mild 
 
Slight pink coloration 
2 – Moderate Definite redness 
3 – Severe  
Marked erythema, bright red to dusky dark red in color 
Hypopigmentation: 
0 – None  
No evidence  
1 – Mild 
 
Slight, barely perceptible 
2 – Moderate Definite, evident 
3 – Severe  
Marked, prominent 
Hyperpigmentation: 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
44 
0 – None  
No evidence  
1 – Mild 
 
Slight, barely perceptible 
2 – Moderate Definite, evident 
3 – Severe  
Marked, prominent 
11.3.2 Tolerability Evaluations 
Tolerability will be evaluated through an assessment, at the time of the study visit, of selected 
local symptoms (i.e., symptoms present at the study drug application site) that include itching, 
burning, and stinging. The subject will self-assess all tolerability symptoms; the assessment will 
be based on an average over the period since the previous study visit.  
For subjects treating (optional) truncal acne, tolerability evaluations will also be conducted on 
this area throughout the course of the treatment/study, and recorded separately. 
Tolerability symptoms that result in the subject’s requiring a concomitant therapy, interruption of 
treatment, or discontinuation from the study, will be reported as an AE. 
Itching: 
0 – None   
No itching  
1-   Mild   
Slight itching, not really bothersome  
 
2 – Moderate  Definite itching that is somewhat bothersome 
 
 
3 – Severe  
Intense itching that may interrupt daily activities and/or sleep  
 
Burning: 
0 – None   
No burning 
 
  
1 – Mild 
 
Slight burning sensation; not really bothersome  
 
2 – Moderate  Definite warm, burning sensation that is somewhat bothersome 
3 – Severe  
Hot burning sensation that causes definite discomfort and may   
 
 
 
 
 
 
 
 
interrupt daily activities and/or sleep  
 
 
Stinging: 
0 – None  
No stinging 
 
  
1 – Mild   
Slight stinging sensation, not really bothersome   
 
2 – Moderate  Definite stinging sensation that is somewhat bothersome 
 
3 – Severe  
Stinging sensation that causes definite discomfort and may interrupt daily 
activities and/or sleep 
11.3.3 Medical History and Abbreviated Physical Examination 
A medical history will be taken at Screening, and confirmed and revised if needed, at Baseline. 
Medical histories having resolved 2 or more years before Baseline need not be collected unless 
considered relevant by the investigator. 
An abbreviated physical examination including measurements of weight and vital signs (blood 
pressure, heart rate, respiration rate, and oral temperature) will be performed at Screening, 
Baseline and Week 12 (end of treatment/study); height will also be measured, but only at the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
45 
Screening visit. Any abnormal physical examination findings will be recorded and evaluated for 
AE reporting. 
11.3.4 Laboratory Tests 
Clinical laboratory analyses (CBC/Diff and serum chemistry) will be conducted on blood 
samples collected from subjects at Baseline and Week 12. All results will be reported, including 
results that are abnormal. Clinically significant results, in the opinion of the investigator, should 
be reported as AEs. If an AE should require laboratory testing, the results of the test must be 
obtained by the study center and filed in the subject’s documentation.  
For pre-menses females and FOCBP, a serum pregnancy test will be conducted at Baseline and 
Week 12.  
11.3.5 Pregnancy Tests 
All females who are pre-menses and FOCBP will undergo serum pregnancy testing at the 
Baseline and Week 12 study visits, and urine pregnancy testing at Screening, prior to 
randomization at Baseline, and at Weeks 2, 4, 8 and 12. The urine pregnancy tests will be 
supplied by the CRO/designee. 
11.4 
Adverse Events 
11.4.1 Definition of Adverse Event 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
the study drug. AEs include any unfavorable and unintended illness, sign, symptom, clinically 
significant laboratory test abnormality, or disease temporally associated with the use of a 
medicinal product that has appeared or worsened during the course of the clinical trial, regardless 
of causal relationship to the study drug(s) under study. The collection of AEs will begin 
following the subject's completion of the consent process to participate in the study. 
11.4.2 Documenting Adverse Experiences 
It is the responsibility of the investigator to document all AEs that occur during the course of the 
study. The AEs should be documented as a single medical diagnosis. When this is not possible, 
the AE should be documented in terms of signs and/or symptoms observed by the investigator or 
reported by the subject at each study visit. Each AE which appears to be independent of any prior 
event will be reported separately. 
All AEs occurring after the subject signs the informed consent through the last study visit must 
be reported, regardless of whether or not the AEs are considered study drug-related. All AEs, 
whether in response to a query, observed by the study center personnel, or reported 
spontaneously by the subject, will be recorded. Any AEs deemed related to treatment reported or 
observed at the final study/treatment visit will be followed until stabilization or resolution. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
46 
At each visit during the study, the subject will be assessed for the occurrence of new and ongoing 
AEs. Cutaneous safety and tolerability signs and symptoms that result in the subject’s requiring a 
concomitant therapy, interruption of treatment, or discontinuation from the study will be reported 
as an AE. The following data will be collected on all AEs and recorded on the appropriate eCRF: 
• Event description (diagnosis preferred, if unknown, record the signs/symptoms) 
• Onset date and end date 
• Maximum intensity (severity) 
• Seriousness 
• Action taken regarding study drug 
• Corrective treatment, if given 
• Outcome 
In addition, the investigator’s assessment of causality will be recorded. 
Vital sign and laboratory abnormalities are to be recorded as AEs only if they are clinically 
significant (for example: are symptomatic, requiring corrective treatment, increased monitoring, 
leading to discontinuation or fulfilling a seriousness criterion). 
11.4.3 Serious Adverse Events 
All AEs will be assessed as either serious or nonserious. An SAE is defined as any untoward 
medical occurrence that, at any dose: 
• Results in death. 
• Is immediately life threatening, (the term “life threatening” in the definition of 
“serious” refers to an event in which the subject is at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it 
were more severe). 
• Requires in patient hospitalization or prolongation of existing hospitalization 
(hospitalization for elective surgery for a baseline condition is not considered an AE). 
• Results in persistent or significant disability/incapacity (permanent or substantial 
disruption of a person’s ability to conduct normal life functions). 
• Is a congenital anomaly/birth defect. 
• Is a medically important event that may not be immediately life threatening or result 
in death or hospitalization, but may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the above listed outcomes; examples of such 
events include, but are not limited to, allergic bronchospasm requiring intensive 
treatment in an emergency room or at home; blood dyscrasias or convulsions that do 
not result in inpatient hospitalization. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
47 
Note: A spontaneous abortion will be considered an SAE, and must be reported to the Sponsor 
within 24 hours of your awareness of the event as outlined under Section 11.4.6. 
11.4.4 Assessment of Severity 
The severity assigned to an AE should be determined by the maximum severity of the AE. The 
categories described below should be used to estimate the severity of AEs: 
• Mild: Transient or mild discomfort which is easily tolerated; no limitation in activity; 
no medical intervention/therapy required. 
• Moderate: Mild to moderate limitation in activity, but does not prevent usual activity; 
some assistance may be needed; no or minimal medical intervention/therapy required. 
• Severe: Marked limitation in activity; some assistance usually required; medical 
intervention/therapy required; hospitalization or prolongation of current 
hospitalization possible; may be incapacitating or life threatening. 
11.4.5 Assessment of Causality 
The investigator should assess the relationship of the AE, if any, to the study drug as either 
“Related” or “Not Related.” The following should be taken into account when assessing AE/SAE 
causality: 
• Related: There is at least a reasonable possibility that the AE/SAE is related to the 
study drug. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the drug and the AE. 
• Not Related: There is little or no reasonable possibility that the AE/SAE is related to 
the study drug. This assessment implies that the AE/SAE has little or no temporal 
relationship to the study drug and/or a more likely or certain alternative etiology 
exists.  
The following should be considered when assessing AE/SAE causality: 
• Positive temporal relationship to study drug, such as if the study drug was withdrawn 
and the SAE resolved, or the event recurred after re-introduction 
• If there is a reasonable possibility that the AE is associated with an underlying or 
concomitant illness 
• Possible association with previous or concomitant therapy 
• No temporal relationship to the study drug and/or a more likely alternative etiology 
exists. 
• If the AE is directly related to study procedures or there is a lack of efficacy 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
48 
11.4.6 Reporting of Serious Adverse Events 
Adverse events classified as “serious” require expeditious handling and reporting to sponsor or 
designee within 24 hours of study center notification to comply with regulatory requirements. 
All SAEs, whether related or unrelated to study drug, must be immediately reported to the 
medical monitor and CRO contact within 24 hours of the investigator’s awareness of the event. 
All SAEs must be reported via secure transmission and must be submitted on a written SAE 
report form signed by the investigator within 24 hours of the investigator’s awareness of the 
event. Contact details for SAE submission and method of secure submission are provided within 
the SAE form. 
Investigators should not wait to receive additional information to fully document the event 
before notifying medical monitor and Sponsor of an SAE. If only limited information is initially 
available, follow-up reports are required. Additional relevant information such as hospital 
records and autopsy reports should be provided to the Sponsor as soon as they are available. 
Should the investigator become aware of an SAE (regardless of its relationship to study drug) 
that occurs within 30 days after stopping the study drug, the SAE must be reported in accordance 
with procedures specified in this protocol. 
All deaths of subjects, regardless of cause, and which are known to the Investigator will be 
reported on the appropriate eCRF for up to 30 days after the administration of study drug, 
regardless of the Investigator's opinion regarding drug relationship. Documentation of the 
subject’s cause of death and a copy of the pseudonymized autopsy or pseudonymized hospital 
report will also be provided. The Medical Monitor and CRO contact must be notified within 24 
hours of knowledge of the event by telephone and submission of an SAE form for all subject 
deaths. Written follow-up must be received by the IRB/IEC and competent authority within five 
(5) calendar days of initial notification as required by local regulations. If cause of death is not 
available within 24-hour reporting period, “death” must be reported as SAE term to meet 
timelines and the cause of death actively queried and submitted as a follow-up as soon as 
available. 
The investigator should take all appropriate measures to ensure the safety of the subjects, notably 
he/she should follow a subject with an SAE until the event has resolved or the condition has 
stabilized. This may imply that follow-up will continue after the subject has left the study, and 
that additional investigations may be requested by the Sponsor. When a SAE persists at the end 
of the study, the investigator will conduct follow-up contacts with the subject until the 
investigator/Sponsor agree the event is satisfactorily resolved and/or stabilized. If at any time 
after 30 days after administration of study drug, the investigator becomes aware of an SAE 
which he/she feels is related to study drug or procedure, this must also be reported immediately 
(within 24 hours of knowledge of occurrence) by telephone and secure transmission to the 
medical monitor and Sponsor and/or Sponsor designee. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
49 
11.4.7 Expedited Serious Adverse Event Reports 
Expedited SAE reports are those that are both unexpected based on the reference document 
(Investigator Brochure) and are related (i.e., the relationship cannot be ruled out) to the study 
drug. The Sponsor will notify regulatory authorities of these AEs and all participating study 
centers in writing for submission by the investigator to the IRB/IEC as required by local 
regulations.  
Upon receiving such notices, the investigator must review and retain the notice with the 
Investigator Brochure and immediately submit a copy of this information to the responsible 
IRB/IEC according to local regulations. The investigator should also comply with the IRB/IEC 
procedures for reporting any other safety information. 
11.4.8 Pregnancy 
All pre-menses females and FOCBP must use an effective method of birth control during the 
course of the study, in a manner such that risk of contraceptive failure is minimized. Abstinence 
is allowed as a birth control method. 
Before enrolling a pre-menses female or FOCBP in this clinical study, the investigator must 
review the following information about study participation: 
• Informed consent requirements 
• Contraceptives in current use 
Following review of this information and appropriate subject counseling, the investigator or 
designee and the subject must sign the informed consent/assent before study enrollment. 
During the study, all pre-menses females and FOCBP should be instructed to contact the 
investigator immediately if they suspect they might be pregnant (eg, missed or late menstrual 
period). 
If a subject or investigator suspects that the subject may be pregnant prior to study enrollment, 
the study drug must be withheld until the results of laboratory pregnancy testing are available. If 
pregnancy is confirmed, the subject must not receive study drug and must not be enrolled in the 
study. If pregnancy is suspected while the subject is receiving study drug, the study drug must 
immediately be withheld until the result of pregnancy testing is known. If pregnancy is 
confirmed, the study drug will be permanently discontinued and the subject will be followed 
until the pregnancy comes to term. A Pregnancy Report Form will be submitted to the sponsor, 
initially and at the end of the pregnancy, which includes the outcome of the pregnancy and any 
complications occurring during the pregnancy or the delivery. If any SAEs are associated with 
the pregnancy, including spontaneous abortion/miscarriage, an SAE form must be filled out in 
addition to the Pregnancy Report Form and submitted as per section 11.4.6.  
All confirmed pregnancies must be immediately reported to the medical monitor and CRO 
contact within 24 hours of the investigator’s awareness of the pregnancy. All confirmed 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
50 
pregnancies are to be reported on a pregnancy form using the same reporting procedure for an 
SAE under Section 11.4.6.  
12 Statistics 
All statistical processing will be performed using SAS® version 9.4 or later unless otherwise 
stated. Statistical significance for superiority analyses will be based on two-tailed tests of the null 
hypothesis resulting in p-values of 0.05 or less. Non-inferiority of IDP-126 Gel to Epiduo® Forte 
will be assessed with 95% confidence intervals.  
The primary method of handling missing efficacy data will be based on estimation using the 
method of Markov Chain Monte Carlo (MCMC) imputation. Estimation will be done for each 
treatment group separately so that the pattern of missingness for one group does not influence the 
estimation of missing data for another group. Groups of complete datasets following the 
estimation will be concatenated to form analysis datasets for the analyses and subsequent 
imputation result inference with SAS PROC MIANALYZE. Descriptive statistics will also be 
derived from the multiply imputed datasets. 
A statistical analysis plan, describing all statistical analyses will be provided as a separate 
document. The SAP will be finalized prior to unblinding of the study treatments. 
Evaluations and Analyses 
Inflammatory lesions and non-inflammatory lesions will be recorded for each subject at Baseline 
and at Weeks 2, 4, 8, and 12. The absolute and percent change from baseline of inflammatory 
lesions and non-inflammatory lesions will be derived for each subject at Weeks 2, 4, 8, and 12. 
The EGSS will be recorded for each Subject. The EGSS will be dichotomized into “success” and 
“failure” at Week 2, 4, 8 and 12 with a subject considered a success for those visits if the EGSS 
is at least 2 grades less than baseline and are Clear or Almost Clear. The TSS will be recorded 
for applicable subjects with truncal acne, and will be summarized at Week 2, 4, 8, and 12, with 
the percentage of subjects achieving at least a 2-grade reduction from baseline included in the 
summary. The TSS will be dichotomized into “success” and “failure” at Week 2, 4, 8 and 12 
with a subject considered a success for those visits if the TSS is at least 2 grades less than 
baseline. 
 Subjects will be asked to complete the Acne-Specific Quality of Life Questionnaire at Baseline 
and Week 12. 
The two IDP-126 Vehicle Gel groups are combined for purposes of analyses. 
12.1 
Assessment of Efficacy 
Primary, secondary and supportive efficacy analyses will be conducted on the ITT (primary) 
population. Primary efficacy analyses will be conducted on the PP (supportive) population. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
51 
12.1.1 Primary Efficacy 
There are three co-primary efficacy endpoints: 
• Absolute change from Baseline to Week 12 in inflammatory lesion counts 
• Absolute change from Baseline to Week 12 in non-inflammatory lesion counts 
• Percentage of subjects who achieve at least a two-grade reduction from Baseline and 
are “Clear” or “Almost Clear” at Week 12 in the EGSS. 
12.1.2 Secondary Efficacy 
The secondary efficacy endpoints will be the following: 
• 
Absolute change in inflammatory and non-inflammatory lesion counts from Baseline 
at Weeks 2, 4, and 8 
• 
Percent of subjects who achieve at least a 2-grade reduction from Baseline and are 
“Clear” or “Almost Clear” at Week 2, 4, and 8 in the EGSS 
• 
Percent change in inflammatory and non-inflammatory lesion counts from Baseline at 
Weeks 2, 4, 8, and 12 
•    Percent of subjects who achieve at least a 2-grade reduction from Baseline at Week 2, 
4, 8 and 12 in the TSS. 
12.1.3 Non-Inferiority for Lesion Count Variables Evaluator's Global Severity Score 
This section provides the basic model and statistical approach which is used in combination with 
the multiple imputation procedures described in Section 12.1.9. Non-inferiority of IDP-126 Gel 
to Epiduo® Forte will be assessed with 95% confidence intervals with the following non-
inferiority margins: 
• Absolute change from Baseline to Week 12 in inflammatory lesion counts: 2.1 
• Absolute change from Baseline to Week 12 in non-inflammatory lesion counts: 2.1 
• Percentage of subjects who achieve at least a two-grade reduction from baseline and 
are “Clear” or “Almost Clear” at Week 12 in the Evaluator’s Global Severity Score: 
10% 
Confidence intervals of the difference in means (IDP-126 – Epiduo® Forte) for the absolute 
change from Baseline in inflammatory and non-inflammatory lesions will be based on 
based on an ANCOVA with factors of treatment and analysis center and the respective Baseline 
lesion count as a covariate If the treatment-by-analysis center interaction effect is significant at 
an alpha less than 0.10, then the effect will be included in the model; otherwise it will be 
removed.  
12.1.4 Test of Superiority for Lesion Count Variables Evaluator's Global Severity Score 
This section provides the basic model and statistical approach which is used in combination with 
the multiple imputation procedures described in Section 12.1.9. Tests of superiority for the 
absolute change from Baseline in inflammatory and non-inflammatory lesions will be based on 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
52 
based on an ANCOVA with factors of treatment and analysis center and the respective Baseline 
lesion count as a covariate If the treatment-by-analysis center interaction effect is significant at 
an alpha less than 0.10, then the effect will be included in the model; otherwise it will be 
removed.  
12.1.5 Statistical Hypothesis Testing and Control of Multiplicity 
In order to control the Type I error rate, testing of primary endpoints will be performed 
sequentially, in the order listed below: 
IDP-126 Gel vs IDP-126 Vehicle Gel  
• Superiority for Dichotomized EGSS 
• Superiority for Absolute Change in Inflammatory Lesion Counts 
• Superiority for Absolute Change in Non-Inflammatory Lesion Counts 
Epiduo® Forte vs IDP-126 Vehicle Gel 
• Superiority for Dichotomized EGSS 
• Superiority for Absolute Change in Inflammatory Lesion Counts 
• Superiority for Absolute Change in Non-Inflammatory Lesion Counts 
IDP-126 Gel vs Epiduo® Forte  
• Non-Inferiority for Dichotomized EGSS 
• Non-Inferiority for Absolute Change in Inflammatory Lesion Counts 
• Non-Inferiority for Absolute Change in Non-Inflammatory Lesion Counts 
• Superiority for Dichotomized EGSS 
• Superiority for Absolute Change in Inflammatory Lesion Counts 
• Superiority for Absolute Change in Non-Inflammatory Lesion Counts 
 If all primary endpoint comparisons are statistically significant, then testing will continue for the 
secondary endpoints in the following order, for IDP-126 Gel vs IDP-126 Vehicle Gel: 
• Percent change in inflammatory lesion counts from Baseline at Week 12 
• Percent change in non-inflammatory lesion counts from Baseline at Week 12 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline and are 
“Clear” or “Almost Clear” at Week 8 in the EGSS 
• Absolute change in inflammatory lesion counts from Baseline at Week 8 
• Absolute change in non-inflammatory lesion counts from Baseline at Week 8 
• Percent change in inflammatory lesion counts from Baseline at Week 8 
• Percent change in non-inflammatory lesion counts from Baseline at Week 8 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
53 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline and are 
“Clear” or “Almost Clear” at Week 4 in the EGSS 
• Absolute change in inflammatory lesion counts from Baseline at Week 4 
• Absolute change in non-inflammatory lesion counts from Baseline at Week 4 
• Percent change in inflammatory lesion counts from Baseline at Week 4 
• Percent change in non-inflammatory lesion counts from Baseline at Week 4 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline and are 
“Clear” or “Almost Clear” at Week 2 in the EGSS 
• Absolute change in inflammatory lesion counts from Baseline at Week 2 
• Absolute change in non-inflammatory lesion counts from Baseline at Week 2 
• Percent change in inflammatory lesion counts from Baseline at Week 2 
• Percent change in non-inflammatory lesion counts from Baseline at Week 2 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline at 
Week 12 in the TSS 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline at 
Week 8 in the TSS 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline at 
Week 4 in the TSS 
• Percent of subjects who achieve at least a 2-grade reduction from Baseline at 
Week 2 in the TSS 
12.1.6 Descriptive Statistics 
Descriptive statistics will be presented for the following parameters by treatment group for both 
the ITT and PP analysis sets: 
• Frequency and percent distributions of the EGSS at Baseline and Weeks 2, 4, 8, and 
12. 
• Frequency and percent distributions of the dichotomized (two-grade reduction from 
Baseline and are Clear or Almost Clear; two-grade reduction from Baseline) EGSS at 
Weeks 2, 4, 8, and 12. 
• Descriptive statistics including mean, median, standard deviation, minimum, and 
maximum will be used to summarize inflammatory and non-inflammatory lesion 
counts at Baseline and Weeks 2, 4, 8, and 12.  
• Descriptive statistics including mean, median, standard deviation, minimum, and 
maximum will be used to summarize the absolute and percent change in 
inflammatory and non-inflammatory lesion counts at Weeks 2, 4, 8, and 12. 
12.1.7 Missing Efficacy Data Imputations 
Lesion Count Variable Missing Data Imputation 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
54 
Missing data will be estimated by multiple imputation and subsequently analyzed. Missing lesion 
count data will be derived for the analysis using the method of Markov Chain Monte Carlo 
(MCMC) multiple imputation. The pattern of missing observations in each treatment group will 
not influence the missing value estimation in the other because the imputation is being conducted 
independently for each treatment group. 
Multiple imputation and subsequent analysis will involve 4 distinct phases with these principal 
tasks: 
 
1. Create a data set of subjects, one for each treatment group, with observed values and 
those needing estimation by MCMC.  The missing lesion count values in each data set 
will be filled in using the MCMC method 5 times to generate 5 data sets.  The resulting 
data sets for each treatment arm will be combined into one complete data set for each 
imputation. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>; 
  where trtpn=(1, 2, 3); 
  mcmc chain=multiple; 
  var baseline week2 week4 week8 week12; 
run; 
3. For each complete data set, the absolute change in lesion counts will be computed. Each 
complete data set will be analyzed as specified for the particular analysis. 
4. The results from these analyses will be combined into a single inference using SAS 
PROC MIANALYZE. 
A total of 6 random seeds will be needed to impute inflammatory lesion counts and non-
inflammatory lesion counts for the five treatment groups. Those 6 random seeds have been pre-
specified by using a random number generator: 
• 
Inflammatory Lesion Counts; IDP-126 Gel: Seed=1228911621  
• 
Inflammatory Lesion Counts; Epiduo® Forte Gel: Seed=1083128177 
• 
Inflammatory Lesion Counts; IDP-126 Vehicle Gel: Seed=138767001  
• 
Non-Inflammatory Lesion Counts; IDP-126 Gel: Seed=239363547  
• 
Non-Inflammatory Lesion Counts; Epiduo® Forte Gel: Seed=1663970906  
• 
Non-Inflammatory Lesion Counts; IDP-126 Vehicle Gel: Seed=1896067066  
EGSS Missing Data Imputation 
A similar procedure will be used for the analyses based on proportion of EGSS successes 
wherein the ANCOVA analysis is replaced with a logistic regression analysis.  Specifically, 
missing EGSS values from which the dichotomized EGSS is derived will be estimated by 
MCMC. The pattern of missing observations in each treatment group will not influence the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
55 
missing value estimation in the other because the imputation is being conducted independently 
for each treatment group. 
The missing EGSS values will be derived for the analysis using the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Multiple imputation and subsequent analysis will 
involve 4 principal tasks: 
2. Create a data set, one for each treatment group, of subjects with observed values and 
those needing estimation by MCMC.  The missing EGSS values in each data set will be 
filled in using the MCMC method 5 times to generate 5 data sets. The resulting data sets 
for each treatment arm will be combined into one complete data set by imputation. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>; 
  where trtpn=(1, 2, 3); 
  mcmc chain=multiple; 
  var baseline week2 week4 week8 week12; 
run; 
3. For each complete data set, the dichotomous success rate (clear or almost clear with a 2-
point change from baseline) will be computed. The 12-week imputed EGSS values will 
be rounded to the nearest integer value prior to evaluating the success rate. Each 
complete data set will be analyzed with a logistic regression with factors of treatment 
group and analysis center. 
4. The results from these analyses will be combined into a single inference using SAS 
PROC MIANALYZE. 
A total of 3 random seeds will be needed to impute EGSS for the five treatment groups. Those 3 
random seeds have been pre-specified by using a random number generator: 
• 
EGSS; IDP-126 Gel: Seed=176867465  
• 
EGSS; Epiduo® Forte Gel: Seed=1813154290  
• 
EGSS; IDP-126 Vehicle Gel: Seed=2066562888  
12.1.8 Subject Self-Assessments 
Subjects will be asked to complete the Acne-Specific Quality of Life Questionnaire (Appendix 
17.3). Descriptive statistics will be used to summarize the data reported for the questionnaire. No 
inferential analyses will be conducted. 
12.2 
Assessment of Safety 
All safety assessments will be conducted using the safety analysis set.  
Safety will be evaluated by tabulations of AEs, and Cutaneous Safety and Tolerability 
Evaluations. Cutaneous Safety Evaluation scores (erythema, scaling, hypo/hyper-pigmentation) 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
56 
and Tolerability (itching, burning, and stinging) will be presented with descriptive statistics at 
Baseline and at Weeks 2, 4, 8, and 12 for each treatment group. In addition, the percent of 
subjects who experience a cutaneous reaction graded at a level of 3 at any point in the study 
following the first application of study drug will be tabulated. Frequencies and percentages for 
each outcome category will be included in these statistics. Mean values will be presented 
graphically by week and treatment group. 
12.2.1 Adverse Events 
All AEs occurring during the study will be recorded and classified on the basis of Medical 
Dictionary for Regulatory Activities (MedDRA) terminology. Descriptions of AEs will include 
the date of onset, the date the AE ended, the severity of the AE, the relationship to study drug, 
the action taken regarding study drug usage, the action taken to treat the AE, and the outcome.  
Treatment-emergent adverse events (TEAEs) are those events with an onset on or after the date 
of the first study drug application. All reported TEAEs will be summarized by the number of 
subjects reporting TEAEs, system organ class, preferred term, severity, seriousness, and 
relationship to study drug. 
Adverse events will be summarized by treatment group and severity. Each subject will be 
counted only once within a system organ class or a preferred term by using the AEs with the 
highest severity within each category. 
Adverse events will be summarized by treatment group and relationship to study drug. Each 
subject will be counted only once within a system organ class or a preferred term by using the 
AEs with the greatest relationship within each category. 
The percentage of subjects reporting AEs will be summarized by treatment group for AEs 
occurring in at least 5% of subjects (in any treatment group). The percentage of subjects for each 
treatment group will be compared using a Fisher’s Exact test. 
All information pertaining to AEs noted during the study will be listed by subject, detailing the 
verbatim term given by the investigator, preferred term, system organ class, start date, stop date, 
severity, action taken, and drug relatedness. The AE onset will also be shown relative (in number 
of days) to the day of initial dose of the randomized study drug. 
Serious adverse events will be tabulated by subject within treatment groups. 
In addition, a list of subjects who discontinued from the study and a list of subjects who 
experienced SAEs will also be provided. 
12.2.2 Safety Laboratory Tests 
Changes from baseline in safety laboratory values will be summarized with descriptive statistics 
at all applicable study visits. Shift tables will be presented for changes in safety laboratory 
values. Normal ranges established by the central laboratory will be used to determine the shifts. 
A listing of all out-of-range laboratory test results at any assessment time point will also be 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
57 
provided. Determination of clinical significance for all out-of-range laboratory values will be 
made by each investigator and included in the listing. In addition, a listing of all clinically 
significant laboratory test results will be provided. 
12.2.3 Vital Sign Measurements 
Changes from baseline in vital sign measurements will be summarized with descriptive statistics 
for each treatment group at all applicable study visits. In addition, shifts in vital sign results 
(normal to abnormal, abnormal to normal, etc., based on the normal ranges) from Baseline to 
Week 12 (or ET) will be summarized using shift tables. 
Individual vital sign test results will be presented in a by-subject listing. A listing of all out-of-
range vital sign measurements at any assessment time point will also be provided. 
12.2.4 Concomitant Medications 
All recorded prior and concomitant medications will be classified based on terminology from the 
World Health Organization (WHO) Drug Dictionary. Therapies and medications data will be 
presented in data listings. 
12.3 
Subject Disposition 
A tabulation of subject disposition will be provided. The tabulation will include the numbers of 
subjects who enter the study, complete the study, and discontinue the study. The reasons for 
discontinuation will be included. 
12.4 
Demographics and Baseline Characteristics 
Subject demographic and baseline characteristics will be summarized by study drug group using 
both the ITT, PP, and the Safety analysis sets. For continuous variables (eg, age), comparisons 
among the 3 study drug groups will be conducted using a two-way analysis of variance with 
factors of treatment and analysis center. Ethnicity and race will be analyzed with a Cochran-
Mantel-Haenszel stratified by analysis center. Past and current medical conditions, as well as 
history of disease, will be presented in data listings and not be compared statistically. 
12.5 
Protocol Deviations 
All protocol deviations will be reported to the Sponsor and recorded throughout the study. A 
tabulation of protocol deviations will be included in a data listing. 
12.6 
Compliance 
The number and percentage of subjects who are compliant in each treatment group will be 
summarized descriptively. Subjects may not miss more than five consecutive days of dosing and 
must take 80-120% of expected doses to be considered compliant. The number of expected doses 
will be determined for each subject based on the length of their participation in the study and will 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
58 
be capped at 89 days; the number of planned doses given a subject attended the Week 12 visit on 
the latest day within window. 
12.7 
Interim Analyses 
No interim analyses are planned. 
12.8 
Additional Statistical Considerations 
12.8.1 Analysis Sets 
Approximately 660 subjects at least 12 years of age and older with moderate or severe acne (a 
score of 3 or 4 [moderate to severe] using the EGSS) will be enrolled and randomized in the 
study. With a 2:2:1:1 randomization ratio, it is anticipated that: 
• 220 subjects to receive IDP-126 Gel, once daily application 
• 220 subjects to receive Epiduo® Forte Gel, once daily application 
• 110 subjects to receive IDP-126 Vehicle Gel (stored at 2-8°C), once daily application 
• 110 subjects to receive IDP-126 Vehicle Gel (stored at CRT), once daily application 
The ITT analysis set will consist of all randomized subjects who received study drug. The safety 
analysis set will be comprised of all randomized subjects who are confirmed to have dosed at 
least once. 
An ITT analysis will be conducted, as well as a PP analysis. Subjects will be eligible for the PP 
analysis if they complete the 12-week evaluation without noteworthy study protocol violations 
(i.e., any subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the study drug or the precise evaluation of study drug efficacy). The PP 
analysis set will include subjects in the safety analysis set who do not meet any of the following 
criteria: 
• Failed any of the inclusion/exclusion criteria. 
• Have taken any interfering concomitant medications. 
• Did not attend the Week 12 visit. 
• Missed more than 1 post baseline study visit prior to Week 12. 
• Have not been compliant with the dosing regimen (i.e., subjects may not miss more 
than 5 consecutive days of dosing and must take 80%-120% of expected doses; the 
number of expected doses will be determined for each subject based on the length of 
their participation in the study). 
• Out of visit window at the 12-week visit. 
Subjects who discontinue from the study due to an adverse event related to study treatment or 
documented lack of treatment effect (and/or worsening of condition) will be included in the PP 
population. Prior to breaking the blind, other additional criteria may be added to the list to 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
59 
accommodate for unforeseen events that occurred during the conduct of the study that result in 
noteworthy study protocol violations.  
12.8.2 Sample Size Determination 
Power calculations are based primarily on the Week 12 results of the Phase 2 study, V01-126A-
201. This study was a five-arm study including IDP-126 Gel versus each of the dual components 
and Vehicle Gel. Furthermore, Component A (BPO 3.1%/adapalene 0.15%) is considered the 
component of IDP-126 which is analogous to Epiduo®, and Epiduo® indicated nearly identical 
reduction in non-inflammatory lesions to Epiduo® Forte Gel. Using estimates from the V01-
126A-201 study for Component A and IDP-126 Vehicle Gel to define the non-inferiority margin 
and for power calculation assumptions allows for the use of estimates within one study thus 
avoiding comparisons between different studies which are under different timeframes and 
different conditions. 
A total of approximately 660 randomized subjects are planned for this study, including 220 
subjects each in the IDP-126 Gel and Epiduo® Forte Gel groups, and 110 subjects each in the 
IDP-126 Vehicle Gel groups, based on the results of the IDP-126A study as below.  
V01-126A-201 Results  
IDP-126 
IDP-126 
Component A 
IDP-126 
Vehicle 
(N=146) 
(N=150) 
(N=148) 
Inflammatory Lesions LSMean (SD) 
29.9 (11.9) 
26.7 (11.7) 
19.6 (12.1) 
Non-Inflammatory 
Lesions 
LSMean (SD) 
35.5 (16.3) 
29.9 (16.4) 
21.8 (16.6) 
EGSS 
Success (%) 
52.5 
27.8 
8.1 
 
A sample size of 220 for the IDP-126 group and 220 for the combined Vehicle Gel group has 
greater than 95% power to detect a statistically significant difference in Inflammatory Lesions, 
Non-Inflammatory Lesions, and in the percentage of subjects who have at least a 2 grade 
reduction at Week 12 from baseline in EGSS and were Clear or Almost Clear with a significance 
level of 0.05. 
A sample size of 220 for the IDP-126 group and 220 for the Epiduo® Forte Gel group has 
greater than 95% power to detect non-inferiority of Inflammatory Lesions, Non-Inflammatory 
Lesions, and in the percentage of subjects who have at least a 2 grade reduction at Week 12 from 
baseline in EGSS and were Clear or Almost Clear with a significance level of 0.05. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
60 
A sample size of 220 for the IDP-126 group and 220 for the Epiduo® Forte Gel group has 
greater than 95% power to detect a statistically significant difference in the percentage of 
subjects who have at least a 2 grade reduction at Week 12 from baseline in EGSS and were Clear 
or Almost Clear with a significance level of 0.05. Additionally, this provides approximately 80% 
power to detect a statistically significant difference in Inflammatory Lesions and greater than 
90% power to detect a statistically significant difference in Non-Inflammatory Lesions based on 
a two-sided t-test and a significance level of 0.05. 
12.8.3 Handling of Missing Data 
The method of multiple imputation will be used (see Missing Efficacy Data Imputations section). 
12.8.4 Multicenter Issues 
 The clinical study will be conducted under a common protocol for each investigational site with 
the intention of pooling the data for analysis.  Every effort will be made to promote consistency 
in study execution at each investigational site. The study is intended to be conducted in a manner 
such that a minimum of 18 subjects will be enrolled for any investigator (i.e., approximately 6 
subjects in each of the IDP-126 Gel and Epiduo® Forte arms and 3 subjects in each IDP-126 
Vehicle Gel arm).  In the event that there are too few subjects for an investigator, then this 
investigator's data will be combined, within geographic region to achieve the desired sample size 
minimum per arm.  The combining of investigator's data will be accomplished by taking the 
investigator with the smallest enrollment and combining it with the investigator with the largest 
enrollment. If there is a further need to combine data, then the data of the investigator with the 
second smallest enrollment will be combined with the investigator's data which had the second 
largest enrollment, and so on.  This process will continue for all investigators who did not have a 
minimum of 18 subjects.  The process of combining investigator data that have insufficient 
subjects per treatment arm will result in redefining the groups of investigators for the purposes of 
statistical analyses.  These combined groups will be referred to as "analysis centers" in the 
statistical analyses based on ANCOVA and stratified logistic testing.  
Prior to investigating the treatment effect within the analysis centers, the magnitude of the site 
main effect will be investigated to determine if the main site-to-site variability is such that it 
could mask the analysis center effects. Thus, prior to pooling, the lesion count data at Week 12 
will be analyzed with an ANCOVA with factors of treatment group, site, and the interaction term 
of treatment group by site and also the percent of subjects with treatment success at Week 12 
will be analyzed with a logistic regression with factors of treatment group, site, and the 
interaction term of treatment group by site. If theses analyses are not computationally feasible 
due to some sites having very few subjects enrolled, the low enrolling sites will be excluded 
from these analyses. 
The consistency of treatment response will be investigated across the analysis centers subsequent 
to combining the data as described above.  Statistical tests will be conducted to identify if there 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
61 
are extreme analysis centers that could affect the interpretation of common statistical and clinical 
conclusions.  An analysis center by treatment interaction will be included in the primary variable 
analyses to test for parallel treatment effect at an alpha level of 0.10.  Change from baseline in 
inflammatory lesions and non-inflammatory lesions will be analyzed with an ANCOVA with 
factors of treatment, analysis center, and treatment by analysis center interaction and the 
respective baseline lesion count variable as a covariate.  For the purpose of testing consistency of 
treatment response, the dichotomized EGSS will be analyzed with a logistic regression procedure 
with factors of treatment, analysis center, and treatment by analysis center interaction. Further 
examination will follow for any variables that have a significant ANCOVA or logistic regression 
interaction term.  In the event that the ANCOVA or logistic regression interaction (referred to 
henceforth as the "appropriate test") p-value is less than or equal to 0.10, a sensitivity analysis 
that excludes analysis centers with the extreme efficacy result will be performed to determine the 
robustness of the treatment effect.  On the other hand, if the outcome of the appropriate test has a 
p-value greater than 0.10, then the conclusions from the pooled data will be considered to be free 
of the impact of extreme analysis centers. 
The first step in conducting a sensitivity analysis is to identify the extreme analysis center or 
centers that contribute to the statistical significance of the appropriate test.  The process involves 
submitting subsets of analysis centers to the appropriate test and observing the appropriate test p-
value for the subset.  Subsets with p-values greater than 0.10 for the appropriate test are 
considered homogeneous. 
The search for an extreme analysis center begins by analyzing all subsets that can be created by 
excluding one analysis center.  If one or more of the subsets result in an appropriate test p-value 
greater than or equal to 0.10, then the analysis center excluded from the subset with the largest p-
value for the appropriate test is deemed to be the extreme analysis center. 
If all appropriate test subset p-values are less than or equal to 0.10, then the process will analyze 
the appropriate test for all subsets that can be created by excluding two analysis centers.  If one 
or more of these subsets generate appropriate test p-values larger than 0.10, then the analysis 
centers excluded from the subset with the largest appropriate test p-value are deemed the extreme 
analysis centers. 
Thus, the process of identifying the extreme analysis centers will continue in a stepwise manner 
by first excluding one, then two, then three, etc., analysis centers until the appropriate test p-
value exceeds 0.10.  
Once the extreme analysis center or centers have been identified, then the treatment p-values of 
the remaining analysis centers will be computed.  Inferences will be drawn from the treatment p-
value, as well as any pertinent observations regarding the extreme analysis center or centers.  
Additionally, it is noted that this process excludes subjects from the analysis in a non-random 
manner and has an unpredictable impact on the power of the treatment effect test.  In the event 
that the treatment effect of the remaining subset is not statistically significant, due consideration 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
62 
of the post-hoc aspects of the process will be given when the results are interpreted.  Conclusions 
will be presented by the sponsor as appropriate to the findings of the sensitivity analysis. 
12.8.5 Multiplicity Issues 
The overall Type I error will be controlled. See Section 12.1.6 for further detail about control of 
Type I error across primary endpoints. 
12.8.6 Windowing Rules 
The timing of all study visits is relative to Baseline (Day 0). The Week 2, Week 4, and Week 8 
visits should occur within ± 3 days of the scheduled times, the Week 12 visit should occur within 
−3/+5 days of the scheduled time. 
13 Quality Control and Quality Assurance 
13.1 
Study Monitoring 
An Investigator Meeting and/or an initiation visit will be conducted with the principal 
investigator and study coordinators by the sponsor and/or its designee. During this meeting, an 
extensive review and discussion of the protocol, the roles of the study staff, all study procedures, 
source documents, and eCRFs will be conducted. Evaluation scales will be reviewed extensively, 
and documentation of training will be recorded for training of Sponsor-approved evaluators. 
The study monitors/clinical research associates will be trained prior to study initiation. Following 
this training, an overview of the study disease and study material background will be understood. 
Specific monitoring guidelines and procedures to be followed during monitoring visits will also 
be presented. During the course of the study, all data will be 100% source document-verified by 
the monitors when possible. All subject source documents must be made available to the 
monitors. 
The conduct of the study will be closely monitored by the sponsor following GCP guidelines. 
The reports of these verifications will also be archived with the study report. In addition, 
inspections or on-site audits may be carried out by local authorities or by the Sponsor’s Quality 
Assurance Department. The investigators will allow the Sponsor’s representatives and any 
regulatory agency to examine all study records, corresponding subject medical records, clinical 
dispensing records and storage area, and any other documents considered source documentation. 
The investigators agree to assist the representative, if required. 
13.2 
Audits and Inspections 
The study will be conducted under the sponsorship of Bausch Health in conformance with all 
appropriate local and federal regulations, as well as ICH guidelines. Interim and end of study 
audits of raw data, study files, and the final report may be conducted by Bausch Health’s Quality 
Assurance Department or designee. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
63 
The Sponsor is responsible for implementing and maintaining quality assurance and quality 
control systems to ensure that studies are conducted and data are generated, documented, and 
reported in compliance with the protocol, GCP, and applicable regulatory requirements. In 
addition, the sponsor will be responsible for securing agreement from all involved parties to 
ensure direct access to all study related study centers, source data/documents, eCRFs, and reports 
for the purpose of monitoring and auditing by the Sponsor, and inspection by domestic and 
foreign regulatory authorities. 
13.3 
Data Quality Assurance 
All assessments performed will be accurately documented in the subject’s source documents and 
eCRFs. The investigator or designee will enter the information required by the protocol into the 
source documents and eCRFs provided by the sponsor or designee. Subjects will be identified in 
the eCRFs by their assigned subject number only. 
The investigators must read the protocol thoroughly and must follow the instructions exactly. 
Any deviations should be agreed to by prior discussion between the sponsor and the investigator, 
with appropriate written protocol amendments made prior to implementing the agreed changes. 
Any amendment containing major modifications (particularly if it may involve an increased risk 
to the subjects) will be approved by the IRB before it may be implemented. No change in the 
conduct of the study can be instituted without written approval from the Sponsor. 
14 Ethics and Administrative Issues 
14.1 
Ethical Conduct of the Study 
This study will be conducted in accordance with the ethical principles originating from the 
Declaration of Helsinki, ICH guidelines, GCP, and in compliance with local regulatory 
requirements. The investigator agrees, when signing the protocol, to adhere to the instructions 
and procedures described in it and thereby to adhere to the principles of GCP. 
14.2 
Ethics Review and Competent Authority Approval 
This protocol, proposed informed consent/assent form, other information to subjects, and all 
appropriate protocol amendments will be properly reviewed and approved by an IRB or IEC and 
the competent authority as required. Documentation of all required approvals must be available 
prior to initiation of the study. The investigator must ensure that IRB or IEC and competent 
authority approvals are in place as required before implementation of protocol amendments or 
amendments to any other study documents. The name and occupation of the chairman and 
members of the IRB/IEC will be supplied to the Sponsor. The investigator will provide required 
progress reports and report all SAEs to the IRB/IEC as required by the IRB/IEC. 
14.3 
Written Informed Consent/Assent 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
64 
Written informed consent/assent, in accordance with local clinical investigation regulations, must 
be obtained prior to participation in the study.  Subjects less than age of consent must sign an 
assent for the study and a parent or a legal guardian must sign the informed consent (if subject 
reaches age of consent during the study they should be re-consented at the next study visit). 
The investigator or designee will discuss the purpose of the study with each subject, and provide 
a description of the study drug (including any potential and possible side effects) and the study 
procedures. Information must be given both in oral and written forms. Subject information will 
be provided in a language understandable to the subject and may not include any language that 
appears to waive any of the subject’s legal rights or appears to release the investigator, the 
Sponsor, or the institution from liability or negligence. 
The investigator will provide the prospective subject sufficient time to consider whether or not to 
participate, minimizing the possibility of coercion or undue influence and will discuss any 
questions the subject may have. The investigator will explain to the subject that participation in 
the study is voluntary and that withdrawal from the study is possible at any time without 
detriment to care. The consent must include acknowledgment that medical records and medical 
data derived from the study may be forwarded to the Sponsor or to responsible local or federal 
authorities. 
No subject can enter the study or have any study related procedures performed before his/her 
written informed consent/assent has been obtained. The original signed and dated informed 
consent/assent form will be retained with the study records, and a copy of the signed form will be 
given to the subject. 
An informed consent/assent template will be supplied by the sponsor or designee. Any changes 
to the informed consent/assent form must be agreed to by the sponsor or designee. Only 
consent/assent forms approved by the IRB/IEC and competent authority, as applicable, must be 
used. 
14.4 
Subject Data Protection 
Subject data will be protected by ensuring that no captured data contain subject names, 
addresses, telephone numbers, email addresses, or other direct personally identifying 
information. Subject data recorded on eCRFs during the study will be documented in a coded 
fashion. The subject will only be identified by the subject number and year of birth. 
Confidentiality of subject records will be maintained to ensure adherence to applicable local 
privacy regulations. Other than where necessary to meet regulatory requirements, all data 
collected in this study will be presented in tabulated (i.e., aggregate) form and listings containing 
information that could be used to identify an individual subject will not be included in any public 
disclosures of the study data or the study results. 
14.5 
Data Monitoring Committee 
Not applicable. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
65 
14.6 
Financial Disclosure 
Financial disclosures will be obtained from all investigators in order to document any potential 
conflicts of interest. An original Financial Disclosure Form (FDF) must be completed, signed 
and dated by the principal investigator (PI) and any sub-investigators and study staff performing 
significant tasks in the study. All FDFs will be collected by the Sponsor or its designee and filed 
in the study Trial Master File. A copy of all FDFs will be retained in the Investigator Site Binder. 
14.7 
Finance 
The study is financed by the Sponsor. 
14.8 
Investigator Obligations 
The investigator agrees, when signing the protocol, to adhere to the instructions and procedures 
described in it and thereby to adhere to the principles of GCP. 
14.9 
Changes to the Protocol 
The investigators must read the protocol thoroughly and must follow the instructions exactly. 
Whenever possible, any planned deviations should be agreed to by prior discussion between the 
sponsor and the investigator, with appropriate documentation of sponsor approval prior to 
effecting the changes agreed upon. Any amendment to the protocol containing major 
modifications (particularly if it may involve an increased risk to the subjects) will be approved 
by the IRB/IEC and competent authority, as applicable before it may be implemented. No change 
in the conduct of the study can be instituted without written approval from the sponsor. 
14.10 Confidentiality/Publication of the Study 
All the data furnished to the investigator and his/her staff and all data obtained through this 
protocol will be regarded as confidential and proprietary in nature and will not be disclosed to 
any third party, except for the FDA or other regulatory body, without written consent from the 
sponsor. 
15 Data Handling and Record Keeping 
15.1 
Inspection of Records 
Investigators must maintain detailed records on all study subjects who are enrolled in the study 
or undergo screening. Data will be recorded in the subject’s source documents and in applicable 
study logs provided by the Sponsor. Source documents include subject medical records, hospital 
charts, clinic charts, investigator subject study files, as well as the results of diagnostic tests 
(eg, laboratory tests). All required data should be recorded in the study documentation 
completely for prompt data review. Upon study completion or at any other time specified by the 
sponsor or designee, the appropriate study documents must be submitted. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
66 
The investigator must keep accurate separate records (source documentation) of all subject visits, 
being sure to include all pertinent study related information. At a minimum, this includes the 
following information: 
• A statement indicating that the subject has been enrolled in the study and the subject 
number 
• Date that informed consent/assent was obtained 
• Evidence that the subject meets study eligibility requirements (eg, medical history, 
screening evaluations) 
• Dates of all study related visits and results of any evaluations/procedures performed, 
including who performed each assessment at each visit 
• Use of any concurrent medications during the study 
• Documentation of study drug accountability 
• Any and all side effects and AEs must be thoroughly documented to conclusion 
• Results of any diagnostic tests conducted during the study 
• The date the subject exited the study and a statement indicating that the subject 
completed the study or was discontinued early, including the reason for 
discontinuation 
Notes describing telephone conversations and all electronic mail with the subject or the sponsor 
(sponsor’s designee) concerning the study must be recorded or kept on file. All source 
documents must be made available to the sponsor and the sponsor’s designated monitor upon 
request. 
15.2 
Retention of Records 
The investigator should properly store and maintain all study records in accordance with sponsor 
directives. All records relating to the conduct of this study are to be retained by the investigator 
until notified by the sponsor in writing that the records may be destroyed. 
The investigator will allow representatives of the sponsor’s monitoring team, the governing 
IRB/IEC, the FDA, and other applicable regulatory agencies to inspect all study records, eCRFs, 
and corresponding portions of the subject’s clinic and/or hospital medical records at regular 
intervals throughout the study. These inspections are for the purpose of verifying adherence to 
the protocol, completeness and accuracy of the data being entered onto the eCRF, and 
compliance with FDA or other regulatory agency regulations. 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
67 
16 References 
1. Bikowski J, Callender V, Del Rosso J, Draelos Z, Tanghetti E. Combining clindamycin 1%-
benzoyl peroxide 5% gel with multiple therapeutic options. Cutis. 2006;78(2 Suppl 1):13-20. 
2. Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/benzoyl peroxide, 
tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and 
tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J 
Drugs Dermatol. 2005;4(5):611-8. 
3. Burkhart CG, Burkhart CN. The chemistry and synergy of benzoyl peroxide with 
clindamycin. Br J Dermatol. 2008;159(2):480-1. 
4. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 
0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007;6(6):616-22. 
5. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream 
and gel compared with tazarotene cream 0.05% and 0.1%. Cutis. 2005a;75(5):289-93. 
6. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream 
and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis. 2005b;75(4):238-43. 
7. Ghali F, Kang S, Leyden J, Shalita AR, Thiboutot DM. Changing the face of acne therapy. 
Cutis. 2009;83(2 Suppl):4-15. 
8. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of 
acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 
2003;49(1 Suppl):S1-37. 
9. Goodman G. Acne--natural history, facts and myths. Aust Fam Physician. 2006;35(8):613-6. 
10. Harper JC. Benzoyl peroxide development, pharmacology, formulation and clinical uses in 
topical fixed-combinations. J Drugs Dermatol. 2010;9(5):482-7. 
11. Kircik L. Community-based trial results of combination clindamycin 1%--benzoyl peroxide 
5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the 
treatment of moderate to severe acne. Cutis. 2007;80(1 Suppl):10-4. 
12. Krakowski AC, Stendardo S, Eichenfield LF. Practical considerations in acne treatment and 
the clinical impact of topical combination therapy. Pediatr Dermatol. 2008;25 Suppl 1:1-14. 
13. Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-
based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 
2012;26(Suppl 1):1-29. 
14. Piskin S, Uzunali E. A review of the use of adapalene for the treatment of acne vulgaris. Ther 
Clin Risk Manag. 2007;3(4):621-4. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
68 
15. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur 
Acad Dermatol Venereol. 2001;15(Suppl 3):43-9. 
16. Tanghetti E, Abramovits W, Solomon B, Loven K, Shalita A. Tazarotene versus tazarotene 
plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-
blind, randomized parallel-group trial. J Drugs Dermatol. 2006;5(3):256-61. 
17. Tanghetti E, Popp K. A current review of topical benzoyl peroxide: new perspectives on 
formulation and utilization. Dermatol Clin. 2009;27(1):17-24. 
18. Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New insights into the 
management of acne: an update from the Global Alliance to Improve Outcomes in Acne 
group. J Am Acad Dermatol. 2009;60(5 Suppl):S1-50. 
19. Thielitz A, Gollnick H. Recent therapeutic developments for acne. Expert Review of 
Dermatology. 2013;8(1):37-50. 
20. Webster GF. Acne vulgaris. BMJ. 2002;325(7362):475-9. 
21. Weiss J, Shavin J. Topical retinoid and antibiotic combination therapy for acne management. 
J Drugs Dermatol. 2004;3(2):146-54. 
22. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of 
acne vulgaris. J Am Acad Dermatol. 1998;39(2 Pt 3):S34-7. 
23. Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg. 
2008;27(3):177-82. 
24. Zar, JH.  Biostatistical analysis.  2nd Edition.  Englewood Cliffs, NJ: Prentice-Hall. P. 118 - 
119. 1984 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
69 
17 Appendices 
17.1 
Subject Instruction Sheet 
These instructions are for the subject and/or the parent/legal guardian. The parent/legal guardian 
should help and monitor study drug application. Study drug should be applied once daily at 
about the same time each day approximately 30 minutes prior to bed time.  Record the 
applications in the subject diary provided. 
 
Study Materials: 
The study drug is provided in a white pump.  
 
First time use of the pump: 
• Prior to first time use, the pump will have to be primed. Remove the cap of the study drug 
pump and fully depress the pump head  
• During priming the product may not immediately come out evenly, or at all, when first 
pressing on the pump head. This is normal. 
• To prime, continue to fully depress the pump head until product comes out evenly from 
the pump nozzle. Product that has come out during priming will be discarded. 
• Priming will be performed during scheduled on-site clinic study visits where new pumps 
will be dispensed under the supervision of the clinic 
 
FOR ALL SUBJECTS APPLYING THE STUDY DRUG TO THE FACE:  
Wash your face gently with a mild cleanser approved by your study doctor and warm (not hot) 
water. Rinse thoroughly and gently pat dry with a cotton towel. Wait until skin is completely dry 
before applying the study drug. 
A thin layer of study drug should be applied once daily in the evening, at least 30 minutes prior 
to bed time (about the same time every day) to the entire face for twelve weeks.  Use the pump to 
dispense one pea-sized amount of study drug onto your fingertip (Figure 1).  One pea-sized 
amount of study drug should be enough to cover your entire face. 
 
 
 
 
This dose should then be dotted on to 6 areas (chin, left cheek, right cheek, nose, left forehead, 
right forehead) on the face (Figure 2). After distributing the dose in this manner, gently rub the 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
70 
gel into the skin. This amount should be used to evenly cover the entire face excluding the 
mouth, eyes and lips. It is important to treat your entire face. 
                                                          
 
 
Do NOT treat only specific lesions. DO NOT APPLY MORE THAN THE PRESCRIBED 
AMOUNT.  Do NOT share your study drug with anybody, study drug is for your use only and 
will be weighed during your study visits to review the amount of study drug you have used. 
Be sure to wash your hands after you apply the product. 
FOR THE SUBSET OF SUBJECTS APPLYING STUDY DRUG TO THE TRUNK: 
Wash the treatment area gently with a mild cleanser approved by your study doctor and warm 
(not hot) water. Rinse thoroughly and gently pat dry with a cotton towel. Wait until skin is 
completely dry before applying the study drug. 
A thin layer of study drug should be applied once daily in the evening, at least 30 minutes prior 
to bed time (about the same time every day) to the entire treatment area (neck, upper chest, upper 
back and shoulders) for twelve weeks. It is recommended that white linen, white towels and 
white clothing is utilized for subjects applying the study drug to the trunk area to avoid 
bleaching.  
You should continue to use the pump to dispense one pea size amount onto the fingertip. The 
study drug should be spread in a thin layer across the truncal area (neck, upper chest, upper back 
and shoulders). It is important that the study drug is spread evenly, and specific lesions are not 
treated. The study drug should become invisible almost immediately following application with 
gentle rubbing.  Ensure to wash your hands after applying the study drug to the trunk and to 
place the cap back onto the pump after each use. 
 
Reminders: 
• On study visit days, study drug will be applied at your study center during the visit. On 
the day of the visit, do not apply study drug prior to your study visit or in the evening 
after your study visit. 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
71 
• Avoid contact with the eyes, inside the nose, mouth and all mucous membranes. Caution: 
This product contains benzoyl peroxide which can bleach hair or colored fabric. 
• Do not cover the affected areas with any type of dressing, such as gauze.  
• THE STUDY DRUG SHOULD BE USED ONLY BY THE PERSON FOR WHOM IT 
WAS PRESCRIBED and it should be kept out of the reach of children or others of 
limited capacity to read or understand. 
• Store this at room temperature up to 25°C (77°F). Do not freeze. Avoid excessive heat or 
cold. 
• Containers of study drug must be returned to the study facility, even if they are empty. 
• If you miss any doses, at your next visit inform the study doctor of the date(s) of the 
missed dose(s). 
• Continue to use the same, study doctor approved, cleanser, moisturizer and sunscreen 
throughout the study. 
• You must not use any other treatment for your facial acne while you are participating in 
this study. 
• Avoid unnecessary sun exposure and tanning booths. 
• It is recommended that white linen, white towels, and white clothing is utilized for 
subjects applying the study drug to the trunk area to avoid bleaching. 
It is important that you inform the study center about any medications (i.e., prescriptions, over-
the-counter medications, street drugs, or herbal medications) that you have taken during the 
study. 
If you experience significant diarrhea while participating in the study contact the Study Doctor 
immediately. 
If you have any questions or have a potential research-related side effect or injury you may 
contact ________________________ at _________________. 
 
Your study drug use by date is: _________________________ (DD/MMM/YYYY). 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
72 
17.2 
Cleansers, Moisturizers and Sunscreen Use Guidelines 
Subjects may use the following products as examples of approved products. The Investigator 
may use their discretion on what products each subject may use in the treatment area during the 
study. Subjects may use the below set of examples or other Investigator approved non-medicated 
products on the treatment area. Information regarding products used should be captured in the 
source document and recorded on the facial skin care section of the eCRF. 
 
Approved Cleanser Examples: 
• CeraVe cleanser 
• Cetaphil daily cleaner and gentle cleansing bar 
• Purpose gentle cleansing wash 
 
Approved Moisturizer Examples: 
• CeraVe Cream or Lotion 
• Moisturel cream or lotion 
• Nutraderm 
• Cetaphil lotion or cream 
• DML 
• Eucerin lotion or cream 
• Purpose 
 
Approved Moisturizer/Sunscreen Combination Product Examples: 
• CeraVe Lotion AM 
• Olay Complete (SPF 15) 
• Neutrogena Health Defense Daily Moisturizer (SPF 30) 
• Cetaphil Daily Facial Moisturizer (SPF 15) 
 
Approved Sunscreen Examples: 
• Banana Boat Sport Sunblock Lotion (SPF 15, 30+ or 50) 
• Neutrogena UVA/UVB (SPF 30 or 45) 
• Neutrogena Sensitive Skin Sunblock Lotion (SPF 17) 
• Neutrogena Healthy Defense Oil-Free Sunblock Lotion (SPF 30 or 45) 
• Coppertone Water Babies UVA/UVB Sunblock Lotion (SPF 45) 
 
 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
73 
 
 
 
 
 
   
    
     
     
    
  
 
 
 
   
    
     
     
    
  
 
 
 
 
   
    
     
     
    
  
 
 
 
   
    
     
     
    
  
 
 
 
 
   
    
     
     
    
  
 
 
 
 
   
    
     
     
    
  
 
 
 
 
   
    
     
     
    
  
 
 
 
 
   
    
     
     
    
  
 
 
 
 
   
    
     
     
    
  
 
 
 
   
    
     
     
    
  
 
 
 
   
    
     
     
    
  
 
 
 
   
    
     
     
    
  
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
74 
 
 
   
    
     
     
    
  
 
 
 
   
    
     
     
    
  
 
 
   
    
    
    
  
   
 
 
   
    
    
    
  
   
 
 
   
    
    
    
  
   
 
  
   
    
     
     
    
  
 
  
   
    
     
     
    
  
 
 
 
 
 
 
 
 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
76 

Protocol V01-126A-202 
 
         Bausch Health 
 
 
Version 2.0, 2 March 2021  
 
CONFIDENTIAL 
77